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The development of a low cost Haemophilus influenzae type b (Hib) manufacturing platform 
at The Biovac Institute (TBI) required analytical method development in parallel with the 
production process development. Technology transfer enabled TBI to develop Hib vaccine 
production which could lead to the development of vaccine manufacturing capacity in sub-
Saharan Africa. Initial studies were conducted in the Research and Development (R&D) 
department from where the process was transferred to the Good Manufacturing Process 
(GMP) environments of the Production and Quality Control departments respectively. 
Scaling of the development process to a process commercially viable required the 
development of additional quality control test methods.  
 
The quality control of Hib is performed by characterisation of the manufactured batch using 
physico-chemical analysis. The data generated are compared against that of a successful 
clinical trial batch. Animal based models for the potency and safety tests of Hib are 
ineffective.  
 
Chromatographic methods of analysis are often used in the pharmaceutical and 
biotechnological industry. Gas chromatography with flame ionisation detection (GC-FID) is a 
conventional technique used for the analysis of volatile analytes. The analysis of process 
residuals ethanol and ethylene glycol were performed using headspace or direct injection 
GC-FID analysis. Ethylene glycol, a non-volatile solvent, was chemically dried after which it 
was derivatised with a trimethylsilylating reagent. In addition, a method was developed to 
determine polyribosylribitolphosphate. Samples were dried by means of lyophilisation and 
then subjected to methanolysis to yield methyl glycosides. A trimethylsilylating reagent was 
used to volatilise the analyte and analysis was performed using GC-FID with direct injection.   
 
The use of internal standards throughout the sample preparation processes minimised errors 
due to sample handling, processing or injector reproducibility. Analytical method validation 
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Quality Control of Haemophilus influenzae type b (Hib) vaccine 
The quality control of Hib conjugate vaccine is performed using physico-chemical test 
methods. Data generated are compared to specifications compiled from a successful clinical 
trial batch. Production of the Hib conjugate vaccine varies and can differ in not only process 
but also polysaccharide size, protein carrier, coupling or conjugation chemistry and final 
formulation. Quality control of process residuals as well as the quantification of 
polyribosylribitolphosphate (PRP) by chromatography will be evaluated.  
1.1  Background 
Hib is a gram-negative coccobacillus encapsulated in the polysaccharide, PRP. The disease 
spreads by means of person-to-person contact through the exchange of nasopharyngeal 
excretions. It is responsible for diseases such as meningitis, epiglottitis, arthritis, cellulitis, 
pneumonia, osteomyelitis and pericarditis. Hib is the leading cause of non-epidemic bacterial 
meningitis in children under 5 years.1  It was listed in 2010 as the cause of 3 million cases of 
serious disease and the deaths of 386 000 children across the world.2 The World Health 
Organisation (WHO) recommended the inclusion of a Hib vaccine in infant immunization 
programs in 1997 in countries where resources were available and where the incidence of 
the disease was high.3 In 2006 the WHO recommended that Hib vaccine should be included 
in all routine infant vaccination programs. The routine administration of Hib vaccine in the 
United States led to a decrease in invasive Hib diseases by between 85-89% from 1983 to 
1995.2  
The immune system recognizes antigens which triggers either antibody production against a 
disease or lymphocytes production. Antibody and cell mediated immune responses can act 
independently or in combination against disease.4 Antibody-antigen reaction is specific and 
is described as a lock and key interaction. Antigens can be divided into T-cell-independent 
and T-cell-dependent. T-cell-dependent antigens require the T-lymphocytes to stimulate 
antibody production by B-lymphocytes. T-cell-independent antigens stimulate antibody 
production without the aid of T-lymphocytes.5 Hib vaccines consisted initially of only the 
capsular polysaccharide. The immune response was as per that for T-cell-independent 
antigens and was weak in infants. Polysaccharide vaccines do not provide long-term 
immune responses. The polysaccharide conjugated to a protein carrier enhanced responses 













The Hib vaccine manufacturers have different production approaches. The vaccines 
produced can differ not only in process, but also polysaccharide size, protein carrier, 
coupling or conjugation chemistry and final formulation.  
Effective Hib conjugate vaccines include: 
 PRP-D, PRP conjugated with diphtheria toxoid (no longer licensed); 
 PRP-CRM, PRP conjugated with a mutated diphtheria toxoid (CRM 197); 
 PRP-OMP, PRP conjugated to a meningococcal outer-membrane protein; 
 PRP-T, PRP conjugated to a tetanus toxoid.3  
1.2  Quality Control 
Traditional vaccine quality control approaches lot release per batch. Each batch of vaccine 
produced is considered as unique. These release tests often rely on potency and safety 
tests in animals.  Animal tests are expensive, have a large amount of variance and have 
ethical considerations. Hib vaccine does not have an animal model to base its batch release 
on. Release of the vaccine is based on a combination of physico-chemical and immuno– 
chemical tests. The lot release approach follows closely that of the more modern and 
humane “consistency approach” in vaccine lot release.  This approach relates all release 
data generated to that of a successful clinic trial batch. The test results obtained when 
testing for lot release are compared to specifications which are generated from data 
obtained from a successful clinic trial.  Quality assurance such as consistency in 
manufacturing processes, monitoring by in–process tests as well as quality control of raw 
materials and or intermediates enables the reproducible production of vaccine. Good 
manufacturing processes (GMP) strengthen the quality assurance of vaccine production 
processes.  This holistic approach to manufacturing vaccines decreases the probability of 
manufacturing a significantly different lot which may not be effective in the clinic.  
Hib vaccine manufacturing can be divided into different stages: 
 Fermentation 
 Polysaccharide purification 
 Polysaccharide activation  














The WHO Technical Report Series (TRS) 897 recommends purified polysaccharide 
characterisation by: 1 
 identifying if the correct antigen was manufactured;  
 determining the size of the polysaccharide by size exclusion chromatography and 
evaluating consistency of the distribution coefficient between manufactured batches; 
 performing quantitative assays for ribose and phosphorus in order to determine the 
composition of the polysaccharide. Ribose content should be ≥ 32 % and phosphorus 
6.8 % - 9 % of polysaccharide determined on dry weight. 
It recommends the characterisation of bulk conjugate by: 1 
 determining the molecular size distribution; 
 the PRP-protein ratio;  
 residual reactive functional groups;  
 residual reagents; 
 total PRP as well as conjugated and unbound/free PRP content. 
Safety tests such as sterility, endotoxin content and specific toxicity of the carrier protein are 
evaluated as well. Potencies of Hib vaccines are directly related to the amount of conjugated 
polysaccharide. The free polysaccharide content is expressed as a percentage of the total 
and conjugated content can be inferred. Vaccines successful in clinical trials had unbound 
polysaccharide levels of < 10% up to 40% of the total PRP content.1  
The Biovac Institute (TBI) is a public private partnership with the aim to produce low cost 
vaccines for sub-Saharan Africa. The manufacturing of a Hib vaccine formed part of a 
technology transfer from an international vaccine partner and was one of the strategies to 
develop vaccine production capacity in South Africa. The manufacturing process was 
developed on a pilot scale in the Research and Development department and then 
transferred to the Production department to upscale for commercial use. There was a need 
to develop quality control test methods using available equipment. 
Quality control methods capable of evaluating removal of residual solvents were needed as 
it was too early in the vaccine development process to illustrate removal by means of 
process validation.1 The control methods could either be performed on the bulk conjugate or 














1.3 Aim and Objectives 
The aim of this study is to apply typical physicochemical test methods to the quality control 
of Hib conjugate vaccines manufacturing. 
The objectives for this study are the development of methods to: 
 determine the concentration of residual ethanol in purified polyribosylribitolphosphate, 
 determine the concentration of residual ethylene glycol in modified 
polyribosylribitolphosphate 
  and quantify the amount of polyribosylribitolphosphate.  
 
In addition to develop an alternative method for quantifying the PRP content. The 
quantification of total and free PRP is both a lot release test and a stability indicating assay. 
The use of non–specific methods of analysis has the risk of interference. Methods of 
quantification that are specific for an analyte limits this risk. The formulation of Hib antigen as 
a part of a multivalent vaccine was also one of the long term objectives of TBI. The 
development of an assay that could in future be applied to Hib antigen quantification as part 
of a multivalent vaccine was needed.  
Chromatographic techniques using gas chromatography will be applied to determine the 
quantity of residual ethanol and ethylene glycol as well as to quantify the amount of PRP in 
the Hib vaccine. Gas chromatographs with flame ionisation detection (GC-FID) are 
conventional laboratory equipment and have been used extensively in the pharmaceutical 
industry. 
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Analytical Method Validation  
Analytical method validation is the documented process of providing scientific evidence that 
an analytical technique is suitable for the purpose it is intended. This chapter provides an 
overview of industry standards with regards to validation parameters.  
2.1 Introduction 
Validation data, through specific laboratory investigations, demonstrate that the performance 
of a method is suitable and reliable for the analytical applications intended.1 Method 
validation ensures that the analytical results generated are within an acceptable uncertainty 
level. 2 Validated analytical test methods are but a part of an integrated quality assurance 











Figure 2.1 Data Quality triangle 3 
The quality assurance of the typical data generation process is illustrated by the Data Quality 
triangle (Figure 2.1). The quality assurance of data is not limited to method validation, but 
encompasses multiple facets. Some are inherent to the test method such as system 
suitability tests whereas others are equipment related such as calibration and functionality or 
operational tests. Equipment must be able to operate at the required specification be it 
quantitation levels or other operating parameters. 
 
Analytical Instrument Qualification  
Analytical Method Validation 
















Equipment related quality assurance begins with User Requirement Specifications (URS), 
Installation Qualifications (IQ) and Operational Qualifications (OQ). A URS documents the 
specific technical requirements of an equipment item by the user. Factors such as 
application, detection limits, site preparation, certification requirements, qualification 
requirements and training requirements are documented. Approval by all stakeholders 
ensures the purchasing of equipment items fit for purpose. IQ protocols documents the 
physical installation process. Execution of the protocol during installation verifies parameters 
such as readiness of the area for the item, verifies that the correct item is installed and that 
all deliverables required from the supplier at installation are met. OQ protocols continue the 
process by verifying that the item delivered is in a functional condition. IQ and OQ protocols 
are executed during the commissioning stages of an equipment item while Performance 
Qualification (PQ) monitors equipment performance for the remainder of its lifecycle. Quality 
assurance during routine analysis after method validation is maintained by system suitability 
tests while equipment is maintained by and is maintained through routine calibration and 
performance testing or qualifications.   
New test methods, modified existing test methods as well as test methods being applied to 
different concentration ranges and sample matrices needs to be validated. Figure 2.2 









  Anticipated in robustness    Not Anticipated 
Figure 2.2 The analytical method life cycle from development phase through analytical 




















Method validation follows the method development process. It is a documented process 
designed around the specific analyte defined prior to the experimental work. A validation 
protocol is generated which includes procedures and acceptance criteria for all 
characteristics. Result are documented in a validation report which also contains the final 
decision deeming the method validated or not.4  The analytical test method is used in the 
routine environment after successful validation, but requires re-validation if any critical 
parameters not previously assessed change. This includes but is not limited to change in 
linear range, sample matrix and instrument model. 
The International Conference on Harmonisation (ICH) categorises analytical procedures for 
validation into four sections: 5 
 Identification tests; 
 Quantitative tests for impurities’ content; 
 Limit tests for control of impurities; 
 Quantitative tests of the active moiety in samples of drug substances or drug product 
or other selected component(s) in the drug product. 
The validation criteria are based on the classification of the analytical test methods above. 
Identification tests for example require only proof of specificity, whereas assays and impurity 
quantification tests require proof of most of the validation parameters. 
2.2 Validation Parameters 
2.2.1 Linearity  
The linearity of an analytical procedure is its ability (within a given range) to obtain test 
results which are directly proportional to the concentration (amount) of analyte in the 
sample.5 See Figure 2.3 for an illustration of linearity in an analytical test method. 
 





























A calibration curve is constructed using analytes of known concentrations. A minimum of 5 
concentrations are required.5 These are plotted through linear regression against the 
response obtained. The y-intercept of the calibration curve should approach zero. An 
intercept with a high value indicates a high response for the blank.  It is possible to 
compensate for this by doing a blank subtraction, thus shifting the calibration curve parallel 
towards zero, see Figure 2.4. A blank containing all components of the sample matrix, 
besides the analyte, is analysed before constructing a calibration curve. Blank response is 
subtracted from the responses of the calibration standards.  
 
Figure 2.4 Blank subtraction  
A y-intercept with a negative value indicates interference or saturation of the response.1 A 
shift in the linear range where the method is used is required. See Figure 2.5. 
 
Figure 2.5 Negative y-intercept 
The calibration curve cannot be used for concentrations lower than 3.0. This would result in 
negative responses being generated. A shift in the linear range to concentrations where 
negative responses are not generated is required.  The United States Pharmacopeia (USP) 
provides guidance as to which concentration ranges should be considered, for different 




































 Assay of a substance: 80% to 120% of the test concentration. 
 Impurity determination: 50% to 120% of the acceptance criterion. E.g. an acceptance 
criterion of 1.0% would require a linear response from 0.5% to 1.2%. 
 Content uniformity: 70% to 130% of the test concentration 
 Dissolution testing: ±20% over the specified range. 
Calibration curves should be designed using standards that include the entire concentration 
range to be analysed. The standards should be evenly spaced across the linear range and 
should include a blank. A correlation coefficient (R) approaching 1.0 is acceptable as it 
indicates closeness or fit of the data points to the line. The R-value should have an absolute 
value that is statistically significant at a 95% confidence level. A R-value of more than 0.90 is 
statistically significant for a calibration plot consisting of 5 data points. The closer the R-value 
to 1.0, the lower the amount of uncertainty when using the plot to calculate unknown 
concentrations.7  
2.2.2 Precision  
The precision of an analytical test method is the measure of the degree of repeatability of an 
analytical method under normal operation. Precision is the level of agreement between 
individual test results, when applying the test method to multiple samplings of a 
homogeneous sample.6 This is expressed as percentage relative standard deviation (% 
RSD) for a statistically significant number of samples. The ICH defines precision as the 
closeness of agreement between a series of measurements obtained from multiple sampling 
of the same homogeneous sample under the prescribed conditions.5 
It can be divided into repeatability and intermediate precision. Repeatability is a measure of 
how reliable the method is to give the same result for the same concentration of analyte. 
This is done by the same analyst on the same equipment over a short period of time.  
Intermediate precision is a study done between different laboratories using the samplings of 
the same sample. The study can also be performed in the same laboratory using different 
pieces of equipment and different analysts.  
The ICH recommends repeatability to be either evaluated on six determinations of 100% of 
the test concentration or nine analyses over the range. Three replicates at the low, middle 















Specificity of the analytical test method has to be studied in order to show that there is no 
interference by components other than the analyte on the response. Components in the 
sample matrix other than the analyte should not suppress or enhance the response 
generated by the analytical procedure. Specificity and accuracy interact closely. Analysis of 
a “placebo” containing all sample components except for the analyte in question should yield 
no or very little response. A response generated would be a reflection of the blank of the 
method. Assuming that this would be the same for all analyses, analysing a blank before 
analysing the sample and then subtracting its response from all subsequent analyses, 
should remove the effect. 
A placebo in most cases does not contain all components present in the sample matrix 
excluding the analyte. Impurities and degradants derived from the analyte would not be 
present. In order to take this into account a spike recovery experiment is more suitable. A 
typical spike recovery experiment is conducted as follows: 
1. Analysis of a sample of known concentration. 
2. Analysis of a known concentration of analyte (typically a reference standard) 
3. “Spiking” a sample as analysed in 1 with the same concentration analysed in 2. 
The response of the combined sample in 3 should be the same or close to the sum of the 
responses obtained for 1 and 2.  
2.2.4 Accuracy 
The accuracy of an analytical procedure is the closeness of test results obtained by the 
procedure to the true value.6  
The accuracy can be tested by using different concentrations of reference standards.  A 
known concentration of reference standard is analysed using the analytical procedure. The 
difference between what is yielded by means of the test method and the actual concentration 
is evaluated. Accuracy is assessed by performing analysis in triplicate over 3 concentrations 
in the low, middle and upper regions of the range.  
The accuracy of the method can also be determined by comparison to a different validated 















2.2.5 Limit of Detection 
The limit of detection is the least amount of analyte that can be reliably detected, but not 
necessarily quantified.6 Analyses of serial dilutions of a known concentration of analyte is 
performed. A distinct difference between the blank analysis and that of the sample must be 
obtained. This could be a colour difference in the case of titrations or the presence of a peak 
in a chromatogram in chromatography. A signal-to-noise ratio of 2:1 is a requirement for 
instrumental analyses.6  
2.2.6 Limit of Quantitation 
The limit of quantitation comprises of both Upper Limit of Quantitation (ULOQ) and Lower 
Limit of Quantitation (LLOQ). These are the highest and lowest concentrations at which the 
analyte can be quantified with accuracy and precision. See Figure 2.6 for an illustration. 
 
Figure 2.6 Limits of Quantitation 
A signal to noise ratio of 10:1 is acceptable for the LLOQ.6 
2.2.7 Range 
The quantification range is the concentration range between the LLOQ and ULOQ that can 
be reliably quantified with accuracy and precision through the use of a concentration- 
response relationship. The validation parameters are all interrelated and in some way affect 

































Figure 2.7 Range  
 
2.2.8 Robustness 
The robustness of an analytical procedure is the measure of its capacity to remain 
unaffected by small but deliberate variations in its parameters. This is assessed during the 
development phase of the analytical procedure.8 Changes made can vary e.g. incubation 
time and or temperature, slightly different volumes of reagents. Establishing this upfront 
during method development also gives an indication of which parameters are critical and 
cannot be changed.  
2.3 Conclusion 
The assessment of a method using qualified personnel, equipment and well defined 
protocols is an essential tool in assuring quality of test methods in a good manufacturing 
practice (GMP) facility. The assumption that a test method is acceptable or fit for purpose 
based on a linear response is invalid. Quantitative tests should at a minimum evaluate 
linearity, precision, specificity and accuracy. Linearity can be evaluated by serial dilutions of 
a known reference concentration and precision by multiple analyses of the same sample. 
Spike-recovery experiments evaluate sample matrix effects on the analysis of the analyte. 
Accuracy can be inferred after linearity, precision and specificity were confirmed.    
Qualitative tests do not need such a comprehensive validation assessment, but limit of 
detection and specificity should be evaluated. Subsequent chapters will evaluate test 
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Development and assessment of an assay to determine residual 
ethanol in batches of polyribosylribitolphosphate (PRP) 
 
Ethanol is used during the purification process of PRP. It is used to elute a salt, formed 
between the negatively charged PRP and a positively charged quaternary ammonium 
species, from a chromatographic column. Excess ethanol is removed from the purified PRP 
concentrate further downstream in the process by means of diafiltration. This assay 
determines the concentration of residual ethanol in the purified PRP concentrate.  
 
3.1 Background 
3.1.1 Haemophilus influenzae type b (Hib) Purification Process 
After fermentation of Hib, the bacteria are heat inactivated. The capsular polysaccharide/ 
PRP are separated from the bacterial cells and subjected to a purification process. 
 
The purification strategy involves the addition of the positively charged quaternary 
ammonium species, hexadecyltrimethylammonium bromide or cetyltrimethyl-ammonium 
bromide (CTAB). The positively charged CTA forms a water-insoluble salt with the negatively 
charged PRP. The CTA: PRP salt precipitates out of the fermentation broth and is filtered/ 
centrifuged out of the solution with the help of a diatomaceous earth filtration aid (Celite). 
  
This Celite slurry/ paste is then loaded onto a chromatographic column and washed with 
copious amounts of aqueous solutions in order to elute excess media and water soluble 
impurities.  
 
Elution of the CTA: PRP salt is performed by stepwise increasing the ethanol concentration 
to a final concentration of ~ 60%.  Fractions containing PRP are identified by a modification 
of a colorimetric assay for ribose. The ethanol: product fractions are collected and combined. 
Addition of sodium chloride (NaCl) to the solution causes the displacement of CTA by sodium 
which renders an alcohol insoluble Na: PRP salt. CTA - Cl stays in the alcohol solution. The 
polysaccharide gets concentrated and purified further by means of diafiltration against a 







































Figure 3.1 Purification process flow diagram 
 
The aqueous purified PRP solution is frozen and stored at temperatures below 0 °C. 
Residual ethanol has exposure limits in pharmaceutical and biological products. This study 
evaluates ethanol content in bulk purified polysaccharide.  
 
3.1.2 Analyte 
Ethanol, also known as ethyl alcohol (chemical formula C2H6O), is a clear, colourless, 
flammable liquid that is miscible with water and most other organic solvents. The melting 
point is – 114.1 °C and boiling point 78.15 °C.  Overexposure can lead to a variety of 
adverse reactions for example irritation of eyes, nose, skin, headache nausea, vomiting, liver 
damage, anaemia, reproductive and teratogenic effects.1 The abovementioned effects 




















3.1.3 Residual Ethanol Specification 
Ethanol is classified as a Class 3 solvent as per USP 34 <467>, Residual Solvents. These 
solvents are deemed as less toxic in short-term studies and negative in genotoxicity studies. 
Pharmaceuticals containing amounts that would lead to a daily intake of ≤ 5000 ppm or 0.5% 
for maximum dosage < 10 grams are acceptable without any justification.2   
 
The International Conference on Harmonisation (ICH) Harmonised Tripartite Guideline 
recommends the use of Class 3 solvents for manufacturing of drug products. Ethanol is 
classified similarly to the USP with a Permitted Daily Exposure (PDE) of 50 mg or less per 
day.3 
 
3.1.4 Method of Analysis of Ethanol 
Class 3 residual solvents are generally considered as non-toxic and a non-specific method 
of quantification may be used.1, 2, 3   Loss on Drying (LOD), a gravimetric analysis, is 
acceptable. The method involves subjecting an accurately weighed mass of sample to a 
specified temperature (typically in an oven) for a given time period. The mass before and 
after the exposure to heat is measured. The difference is expressed as a percentage of the 
original mass.  The same method of analysis applies to samples where the drying occurs 
either over a moisture absorbent chemical or under a vacuum. A major disadvantage of this 
technique is the relatively large quantity of sample that is required. Other similar techniques 
include thermal analysis and thermogravimetric analysis. This method of analysis is however 
not applicable or viable for the purified PRP as it is in an aqueous solution. 
 
Spectrophotometric techniques, making use of kits where ethanol reduces dichromate to a 
blue chromic colour, are available.4 The sample absorbance is measured on a 
spectrophotometer at the absorbance maximum, 580 nm. A detection range of 0.04% to 4% 
is listed. A kit making use of an enzyme-catalysed kinetic reaction claims to be a more 
sensitive method with a detection limit of 0.0008% to 0.1%.5 
 
The conventional method of analysis for residual solvents and organic volatile impurities is 
gas chromatography (GC).  Gas chromatography with flame ionisation detection (GC-FID) is 
an extremely sensitive and robust technique. It has a wide linear detection range and is 
reliable.6 Methods of sample introduction using GC-FID include but are not limited to static 
headspace, purge and trap extraction, multiple headspace and direct injection. Capillary 
columns are used resulting in excellent resolution. Columns can be either wide bore or 












analyte in the sample is compared to that of a standard of known concentration. The 
concentration of the analyte in the sample matrix can be calculated provided the 
concentration fall within the linear detection range of the chromatographic test method.  
 
Direct injection is the oldest GC sample introduction technique and is simple and reliable. 
The sample is dissolved in a high boiling point solvent which elutes much later than that of 
the analyte minimizing or preventing interference. Direct injection from the autosampler vial 
with an autosampler or even manually with a syringe is done directly into the heated 
injection port.  Non-volatile components of the sample matrix are also injected. Column 
efficiency and lifespan as well as detector sensitivity can become compromised. The non-
volatile components or high boiling sample matrix could result in carry over and interfere with 
subsequent analysis. This non-volatile component of the sample matrix could also remain in 
the split/splitless inlet liner of the GC. This technique also has a lower detection limit 
compared to the other GC sample introduction techniques.6  
 
Headspace analysis has an advantage over direct injection in that only the volatile analytes 
in the sample matrix are injected. This sample introduction technique extends the lifetime of 
the columns and prevents contamination of the injector. 7   
 
Purge and trap (Dynamic Headspace) makes use of an extraction process whereby all 
solutes are extracted from the sample and trapped in an adsorbent trap. The sample is 
thermally desorbed from the trap and injected into the GC. Volatile organic compounds, with 
poor water solubility and boiling points lower than 200 °C, are concentrated. Volatile organic 
compounds soluble in water can be extracted this way as well, but the limit of quantification 
would be higher than the aforementioned water insoluble compounds. Purging efficiency is 
lower and higher temperatures and longer purging is required. An inert gas is bubbled 
through the aqueous sample matrix which leads to the liberation of the volatile organic 
compounds. The compounds are in turn adsorbed to the trap which is composed of multiple 
layers of different types of sorbent material.8 Different traps exist for different types of 
compounds. Traps have a finite lifecycle and replacement is needed after time. Purge and 
trap techniques are not readily automated and repeated cleaning of glassware is required. It 
is however more sensitive than static headspace injection.9 See Figure 3.2 for a diagram of 













Figure 3.2 Schematic diagram of dynamic headspace device coupled to a gas 
chromatograph.6 
 
Purge and trap or dynamic headspace analysis has lower precision compared to static 
headspace analysis.6 
Static headspace has relatively simple method development and can be automated to 
accommodate a large number of samples. Interference caused by samples containing highly 
volatile analytes, which can interfere with the analysis of analytes with different volatilities, is 
decreased or prevented. Static headspace methods have a wide use where the sample is 
dissolved in a liquid matrix.9 The technique has some drawbacks that have to be managed 
e.g. reproducibility, matrix effects and sensitivity for samples with low water solubility.6 
Figure 3.3 illustrates a typical static headspace sample vial.10  
 












This method was initially used to measure the solubility of anaesthetics and for the analysis 
of gases, alcohols and solvents in biological samples.11 The vial is subjected to a constant 
temperature until the volatile analyte have equilibrated between the liquid and gas phases. 
Optimum sensitivity is achieved when the distribution coefficient has a small value. The 
distribution coefficient is related to the concentration of the analyte in the gas or liquid phase 
by the equation: 
 
K = ConcentrationLiquid/ConcentrationGas  (K = CL/CG). 
 
The following equation describes the equilibrium: C0 1 X VL = CLVL + CGVG 
 
C0 1 = analyte concentration in the liquid phase before equilibrium  
CL and CG = equilibrium concentrations 
VL and VG = volumes in the liquid and gas phases.11 
 
This can be affected by means of adjusting the pH, “salting out” or increasing the 
thermostating temperature.9 Increasing the temperature of the vial would result in a 
decrease in solubility of the solvent in solution leading to a higher concentration of it in the 
gaseous phase.11 The headspace of the vial would then contain the analyte in a gaseous 
phase which is relatively clean and readily available for injection via a gastight syringe or 
autosampler.  
 
Static headspace with GC-FID will be used to determine the ethanol content in PRP. The 
analyte is easily dissolved in water and use of an internal standard will improve 
reproducibility. Multiple samples can be incubated simultaneously allowing for a quicker 
process time.  
 
3.2 Experimental 
3.2.1 Test Samples  
 Purified PRP batch # P67, The Biovac Institute. 
 Ethanol, Merck, CAS number 64-17-5 
 Iso-propanol, Merck,  CAS number 67-63-0 
 
3.2.2 Reagents 














 Agilent 7890 Gas chromatograph 
 CTC PAL autosampler 
 Reacti-vap/ Reacti-therm sample evaporation unit, Thermo Scientific 
 Eppendorf pipettes, 200 µl, 1000 µl 
 Sartorius CP225 D 5 – place balance 
 
3.2.4 Column Selection 
Column selection was based on polarity of the analyte, lifetime of the column as well as 
analysis time. The J&W Scientific DB 624 column with length 30 m, diameter 0.53 mm and 
film thickness 3.0 µm was used. The column is mid polar and has a temperature limit of  
250 °C with a longer lifetime compared to more polar columns. It has a polyethylene glycol 
stationary phase and the diameter can accommodate the high carrier gas flows typically 
used in headspace analysis. The stationary phase film is thick to minimize interaction of the 
column wall with the analyte.  
 
3.2.5 Method Parameters 
Headspace unit 
 
 Incubation temperature: 80 °C 
 Incubation Time: 300 seconds 
 Syringe temperature: 50 °C 





 Heater : 250 °C 
 Mode: Split 
 Split ratio: The split ratio for the higher concentration evaluation was 35:1 and  that of 
the lower 10:1 
 Total flow: 39 ml/minute 
 Septum purge flow: 3 ml/ minute 
 
Flow parameters 
 Flow rate: 1 ml/minute 














 Equilibration time: 3 minutes 
 Oven Program: 
50 °C hold for 5 minutes 
10 °C/ minute to 200 °C hold for 5 minutes 
Run Time 25 minutes 
Detector unit 
 
 Hydrogen: 200 ml/minute 
 Nitrogen  :300 ml/minute 
 Air           : 400 ml/minute 
 
The oven temperature program and column flow was determined by using a resolution 
solution of ethanol and the internal standard, iso-propanol. The parameters yielding optimum 
peak separation, shape and retention were selected. 
 
3.2.6 Sample Preparation 
A volume of 1.0 ml of the sample to be analysed was added to a headspace vial containing 
2.0 g of anhydrous sodium sulfate and 1.0 ml of the internal standard solution. Additional  
3.0 ml purified water was added before sealing.  
 
3.2.7 Internal Standard Selection 
Iso-propanol was chosen as the internal standard. It has a boiling point of 82.5 °C and is 
miscible with water and alcohol. The response of iso-propanol is comparable to that of 
ethanol at similar concentrations. Resolution between the ethanol and iso-propanol peaks in 
the chromatogram is more than the USP calculated resolution factor of 2.0. See Figure 3.4 
for the internal standard chromatogram.  
 













The retention time of iso-propanol relative to that of ethanol is 1.07. See Figure 3.5 for a 
chromatogram of ethanol and iso-propanol. 
 
 
Figure 3.5 Chromatogram of iso-propanol, ethanol resolution solution 
 
3.2.8 Sample Incubation Temperature 
In order to determine the temperature at which the maximum amount of analyte is available 
in the gaseous phase of the headspace of the vial, incubation temperature was investigated.  
A sample solution containing 10 ppm of ethanol and 10 ppm of iso-propanol was prepared. 
5.0 ml of the solution as well as 1.0 g of anhydrous sodium sulfate were placed in 
headspace vials and analysed using different incubation temperatures. Incubation time was 





Figure 3.6 Incubation temperature vs. response 
An increase in response is directly proportional to an increase in incubation temperature. 








































of the vial as a result of the increased temperature. A temperature below the boiling point of 
water, but well above that of the volatile components was selected. This prolongs the column 
life by limiting the amount of water vapour and water soluble impurities being introduced. 
 
3.2.9 Sample Incubation Time 
The effect of incubation time at a constant temperature was investigated. The minimum 
amount of time needed to incubate a sample providing maximum availability can be 
determined. A sample solution containing 10 ppm of ethanol and 10 ppm of iso-propanol 
was prepared. 5.0 ml of the solution as well as 1.0 g of sodium sulfate anhydrous were 
placed in headspace vials and analysed using different incubation times. Incubation 





Figure 3.7 Incubation time vs. response 
The ethanol and iso-propanol response increased with an increase in time, but started to 
plateau at about 5 minutes. This can be attributed to equilibrium being reached between the 
sample and the headspace of the vial. There was no significant change in response when 
increasing the incubation time for ethanol. Optimum incubation time was 5 minutes as 














































3.2.10 Salt Addition 
Salt concentration in the headspace vial was varied. This was done using both sodium 
chloride and sodium sulfate. The effect of salt concentration on both ethanol and iso- 
propanol response was investigated. A sample solution containing 10 ppm of ethanol and  
10 ppm of iso-propanol was prepared. In separate vials to 5.0 ml of the solution different 
masses of sodium sulfate and sodium chloride were added. Incubation time was set at 
5 minutes and incubation temperature at 70 °C. See Figure 3.8 for a plot of the effect of salt 




Figure 3.8 Salt concentration vs response 
 
An increase in salt concentration elicits an increase in sample response. Sodium sulfate 
addition results in a higher response when compared to that of sodium chloride at a similar 
concentration. Sodium sulfate has a greater “salting out” effect on the two alcohols 
compared to sodium chloride. There is a strong intermolecular interaction between water 
and the salt. This interaction is affected by ionic radius and thus electrostatic field.12 The 









































3.3 Results and Discussion 
In order to assess the suitability of the method to determine ethanol content in bulk purified 
PRP, validation parameters linearity and range, specificity, precision and accuracy were 
evaluated. 
 
3.3.1 Linearity and Range 
The linearity was assessed by making up solutions of ethanol in purified water of different 
concentrations ranging from 50 ppm to 1000 ppm with an internal standard concentration of 
500 ppm. The range was determined from the linear portion of the graph.  
 









50 397634 2937361 0.135371 
100 719991 2856853 0.252022 
500 3380004 2772061 1.219311 
1000 7050994 2667975 2.642826 
2000 15064630 2855055 5.276476 






Figure 3.9 Ethanol response vs. concentration  
 
The range was found to be linear throughout with a correlation coefficient of 0.9994 from a 
concentration of 50 ppm to 5000 ppm.  
y = 0.0025x + 0.0569 






































In order to accommodate for results in the lower concentration ranges, linearity was re-
assessed between 0.25 ppm and 10 ppm with an internal standard concentration of 15 ppm. 
 
Table 3.2: Results obtained for the linearity and range study 0.25 ppm to 10 ppm 









0.25 33139 1814861 0.0183 
0.5 60979 1935891 0.0315 
1 107605 1786153 0.0602 
2.5 254838 1724642 0.1478 
5 510530 1725103 0.2959 





Figure 3.10 Ethanol response vs. concentration 
The range was found to be linear with a correlation coefficient of 0.9998 from a 
concentration of 0.25 ppm to 10 ppm. The correlation coefficients of both data sets are close 
to 1 indicating a good fit of the data points to the regression line. The y-intercepts for both 
concentration ranges approaches zero.  The effect on results generated would have an 





y = 0.0603x - 0.0002 







































Specificity was evaluated by testing a specific volume of polysaccharide solution spiked with 
a standard of a known concentration of ethanol (250 ppm). The same volumes of 
polysaccharide and standard were tested independently and the ethanol value of the spiked 
polysaccharide compared to the sum of the individual polysaccharide and standard 
solutions. The internal standard concentration was 500 ppm. 
 












PRP + Std 1671704 2619021 0.64 233.24 
96.57 PRP + H2O 0 2971596 0 0 
Std + H2O 1856976 2998373 0.62 225.24 
  
The recovery was calculated using the equation below:   
 
% Recovery = [(PRP + H2O) + (Std + H2O)]/ (PRP + Std) X 100 
 
The results indicate that the other components present in the polysaccharide do not interfere 
with the ethanol assay. All sample matrix effects can be eliminated based on this. There is 
no reference made by the ICH Guideline Q2 (R1), Validation of Analytical Procedures: Text 
and Methodology as to what the acceptance criteria for specificity should be. The 




Precision was assessed by analysing an ethanol concentration six times. The % RSD was 
calculated and reported.  Standard solutions with concentrations within the two different 
linear ranges were prepared and analysed. Concentrations of 100 ppm and 5.0 ppm were 

















Table 3.4: Results obtained for the precision study using a 100 ppm solution 





100 716526 2845385 0.25 
100 762032 2919793 0.26 
100 727647 2736371 0.27 
100 749210 2950442 0.25 
100 730142 2884549 0.25 
100 727561 2714912 0.27 
Average 735519.7 2841908.7 0.26 
Standard Deviation 16765.0 96893.8 0.010 
% RSD 2.3 3.4 3.846 % 
 
 
Table 3.5: Results obtained for the precision study using a 5.0 ppm solution 





5.0 543135 1864098 0.29 
5.0 523973 1761900 0.30 
5.0 478214 1591590 0.30 
5.0 506628 1741606 0.29 
5.0 517491 1727667 0.30 
5.0 493740 1663755 0.30 
Average 510530.2 1725103 0.30 
Standard Deviation 22950.86 92240.83 0.005 
% RSD 4.495495 5.346976 1.667 
 
Repeated analysis of the same sample yielded a low % RSD for both data sets. The  
100 ppm solution had a % RSD of 3.85 % and the 5.0 ppm solution 1.67 %. The variances 




















Accuracy was assessed by the triplicate analyses of 3 different concentrations from the 
lower, middle and upper region of the linear range. The average, standard deviation and 
% RSD of each sample set was determined.  
 
50 ppm, 500 ppm and 1000 ppm ethanol in purified water were analysed. The result of the 
500 ppm solution was treated as the “actual” concentration.  The internal standard 
concentration was kept constant at 500 ppm. 
 









362566 2834692 0.127903 
380684 2924594 0.130166 
374837 2891780 0.129622 
Average 372695.7 2883689 0.12923 
Standard deviation  9246.862 45493.9 0.001181 
% RSD 2.481076 1.577629 0.914081 
 
500 
3827307 3048885 1.255314 
3758255 3029023 1.240748 
2789331 2270133 1.228708 
Average 3458298 2782680 1.24159 
Standard deviation  580370 443990.1 0.013323 
% RSD 16.78196 15.95548 1.073035 
    
1000 
7325346 2915809 2.512286 
6584379 2663942 2.471668 
6395010 2583855 2.474988 
Average 6768245 2721202 2.486314 
Standard deviation  491666.9 173226.4 0.022554 













Accuracy was re-assessed in a lower concentration range as in the case of linearity before 
using concentrations 1.0 ppm, 2.5 ppm and 5.0 ppm. The internal standard concentration 
was kept constant at 15 ppm. 
 









105474 1802760 0.058507 
109237 1759730 0.062076 
108103 1795969 0.060192 
Average 107604.7 1786153 0.060258 
Standard deviation  1930.361 23133.54 0.001785 
% RSD 1.793938 1.29516 2.962986 
 
2.5 
249561 1715461 0.145478 
260934 1763487 0.147965 
254020 1694979 0.149866 
Average 254838.3 1724642 0.147769 
Standard deviation  5730.492 35164.74 0.002201 
% RSD 2.248677 2.038959 1.48937 
 
5.0 
506628 1741606 0.290897 
517491 1727667 0.299532 
493740 1663755 0.296762 
Average 505953 1711009 0.29573 
Standard deviation  11889.87885 41512.68 0.004409 
% RSD 2.349996709 2.42621 1.490843 
 
The recovery was calculated using the equation: % Recovery = (Actual/ Theoretical) X 100% 
The response obtained for the 500 ppm concentration was used to calculate the 50 ppm and 
1000 ppm recovery.  
 
50 ppm = [0.12923/ (1.24159/10)]*100 = 104.1 % 












The response obtained for the 2.5 ppm concentration was used to calculate the 1.0 ppm and 
5.0 ppm recovery. 
  
1.0 ppm = [0.060258/ (0.147769/2.5)]*100 = 101.9% 
5.0 ppm = [0.29573/ (0.147769*2)]*100 = 100.1% 
 
The amount of variance, of the triplicate analyses of the different solutions, was relatively 
low. The data obtained for the accuracy study at the higher concentration, yielded the lowest 
% RSD for the 50 ppm and 1000 ppm solutions with values of 0.91%.  The triplicate analysis 
of the 500 ppm solution yielded a %RSD of 1.07%. Recoveries for the 50 ppm and          
1000 ppm solutions, when using the response of the 500 ppm solution as the reference, 
were calculated as 104.1% and 100.1%.  
 
The data obtained for the analysis of the lower concentrations had the lowest %RSD at the 
2.5 ppm and 5.0 ppm concentrations with values of 1.49 % for both.  The highest %RSD of 
2.96 % was obtained for the analysis of the 1.0 ppm solution. Recoveries for the 1.0 ppm 
and 5.0 ppm solutions, when using the response of the 2.5 ppm solution as the reference, 
were calculated as 101.9% and 100.1%.  
 
The recoveries for both the higher and lower concentrations were within acceptable limits. 
The data generated also confirms the precision of the test method as triplicate analysis over 














The determination of the ethanol content in bulk purified PRP using GC-FID analysis was 
evaluated. Ethanol is classified as a Class 3 solvent and there are limitations on daily 
intake.2,3 The samples were analysed using GC-FID, static headspace with iso-propanol as 
an internal standard. Sodium sulfate was used to increase the availability of analyte in the 
gaseous phase. The incubation temperature and time used for the headspace oven were 80 
°C and  5 minutes respectively. Chromatography was performed using a mid polar capillary 
column with polyethylene glycol as the stationary phase. Nitrogen was used as the carrier 
gas and the oven temperature was governed by a temperature program. In order to 
determine the suitability of the method, the validation parameters linearity and range, 
specificity, precision and accuracy were evaluated. Robustness was assessed by evaluating 
incubation time and temperature as well as salt concentration. 
 
The linearity of the 50 ppm to 5000 ppm range had a R2 value of 0.9994 and the 0.25 ppm to 
10 ppm range had a R2 value of 0.9998. The recovery for the specificity study was 
determined as 96.88%, the precision study of the 100 ppm solution yielded a %RSD of 
3.85% and that of the 5.0 ppm study 1.67%. The recovery of the 50 ppm solution was 
determined as 104.1%, the 1000 ppm as 100.1%, the 1.0 ppm 101.9% and the 5.0 ppm 
solution as 100.1%. The developed method meets all validation acceptance criteria for both 
the 50 ppm to 5000 ppm and 0.25 ppm to 10 ppm concentration ranges. The retention times 
of both the ethanol and iso-propanol peaks in the chromatographs were less than 15 
minutes. The peaks were well separated in the chromatographs and peak shapes were 
good. Baseline separation with a resolution between the peaks of more than 2.0 as well as a 
tailing factor of less than 2.0 was met.  Sample preparation was minimal and total analysis 
time was relatively short. The method was shown to be robust and can be implemented in a 
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Development and assessment of an assay to determine residual 
ethylene glycol in oxidized polyribosylribitolphosphate (PRP) 
 
The PRP polysaccharide is treated with sodium periodate to prepare the activated PRP 
intermediate which is subsequently conjugated to the protein carrier to form the Hib 
conjugate vaccine. The controlled periodate oxidation serves to both depolymerise the PRP 
polysaccharide to a size that is required for conjugation, as well as generate terminal 
reactive aldehyde groups required for the conjugation reaction. The sodium periodate 
oxidation reaction is quenched by the addition of excess ethylene glycol and the activated 
PRP recovered after diafiltration. This assay determines the concentration of residual 
ethylene glycol in the activated PRP. 
4.1 Background 
 
4.1.1 PRP Oxidation/ Modification Process 
 
After purification of the polysaccharide of Haemophilus influenzae type b (Hib), the long 
chain length polysaccharide needs to be size reduced and activated prior to conjugation with 
a protein. Sodium periodate is used to cleave the polysaccharide to form shorter 
oligosaccharides having reactive aldehyde groups. The reaction takes place under controlled 
temperature for a set time. The oligosaccharide terminates in reactive aldehyde functional 
groups at both terminals of the chain (Figure 4.1). 
 













Formation of the oligosaccharide is monitored by size exclusion chromatography (SEC- 
HPLC) using refractive index (RID) as the means of detection. Molecular weight markers are 
used to calculate a distribution coefficient of the analyte.1 The size distribution of the 
molecule is determined by means of retention time. Chromatograms of the molecular weight 
markers, PRP and activated PRP are shown in Figures 4.2, 4.3 and 4.4.  
 
 
Figure 4.2 Chromatogram of molecular weight markers 
 
 
Figure 4.3 Chromatogram of PRP 
 
 













Size exclusion chromatography is a chromatographic technique that can be applied to 
analytes with a high molecular weight. Analytes are separated in a sample matrix based on 
size. Size exclusion columns are packed with particles with a specific pore size. The packing 
forms a mesh through which the analyte must migrate or travel. Lower molecular weight 
molecules travel a longer path as they diffuse through both the spaces between the 
individual silica beads and the pores within the silica beads. They are subsequently retained 
longer. Molecules with a larger molecular weight penetrate the pores of the silica to a lesser 
extent and elute relatively early These molecules are of a size larger than that which the 
pores in the beads permits to enter, are excluded and travels only between the silica beads 
with no or little retention. There is an indirect correlation between elution time and molecular 
weight. The smaller the molecule the later it elutes whereas the larger the molecule the 
earlier it elutes.2 The long chain purified PRP has a large hydrodynamic size and elutes at ~ 
13.6 minutes whereas the shorter chain length activated PRP elutes at ~ 17 minutes.  
 
The addition of ethylene glycol consumes or quenches the excess sodium periodate in the 
reaction mixture stopping the oxidation. Tangential flow diafiltration is used to remove 
excess reagents like sodium periodate and ethylene glycol as well as short chain 
oligosaccharides that are not included in the fraction that is conjugated. This filtration 
technique has the fluid pumped tangentially to the filtration membrane. Additional pressure is 
applied perpendicularly to the membrane. The result is a filtration process whereby the 
molecules too large to pass through the membrane are being swept along with the flow of 
the fluid. Blockage of the filter is prevented or delayed with this approach as opposed to 
“normal” filtration processes. A reservoir with a buffer solution replaces the filtrate 
substituting undesired components and salts with the buffer solution. After several passes, 
the amount of buffer used to replace the filtrate is reduced and this serves as a mechanism 
to concentrate the activated PRP. This chapter evaluates residual ethylene glycol content in 
the activated PRP intermediate.  
 
4.1.2 Analyte: Ethylene Glycol 
 
Ethylene glycol, also known as 1, 2-ethanediol (chemical formula C2H6O2), is a clear, 
viscous liquid with a sweet taste that is very hygroscopic and able to absorb twice its weight 
in water at 100% humidity. See Figure 4.1 for the molecular structure.  It is miscible with 
water and most other organic solvents. The melting point is – 13 °C and bp 760 of 197.6 °C.3 
 












Ethylene glycol is commonly used in anti-freeze solutions in the cooling systems of motor 
vehicles.  Due to its misleading sweet taste it is often ingested. The initial effects are those 
of alcohol consumption thus accidental fatality due to overexposure by ingestion is common. 
Ethylene glycol poisoning can be fatal with the initial effect being suppression of the central 
nervous system followed by nausea and vomiting.3  
 
Depending on the exposure as well as time before treatment, victims can lapse into a coma 
with renal and cardiopulmonary failure within 24 to 72 hours. The formation of glycolic, 
glyoxalic and oxalic acid by ethylene glycol metabolism results in metabolic acidosis.4 
Treatments include pumping the stomach after ingestion, activated carbon treatment, 
sodium bicarbonate intravenously to reverse acidosis and haemodialysis to remove ethylene 
glycol metabolites from the bloodstream.5 
 
4.1.3 Residual Ethylene Glycol Specification  
 
Ethylene glycol is classified as a Class 2 solvent in the United States Pharmacopeia (USP) 
34 <467> Residual Solvents. These are solvents that need to be limited in use due to their 
inherent toxicity.  It has a daily permitted intake limit of less than 620 ppm or 6.2 mg/day.6   
 
The International Conference on Harmonisation (ICH) Harmonised Tripartite Guideline 
classifies ethylene glycol similarly to the USP with a Permitted Daily Exposure (PDE) of 
6.2 mg per day.7 The above limits are applicable to pharmaceutical products where the daily 
intake of the product does not exceed 10 grams.  
 
There is no specification available for the presence of ethylene glycol in Hib vaccines. The 
World Health Organization (WHO) Technical Report Series (TRS) 897 Annex 1, 
Recommendations for the production and control of Haemophilus influenzae type b 
conjugate vaccines, states that residual active functional groups should be shown to be 
removed after final processing by means of validated test methods. Residual reagents and 
reaction by-products should be removed during the conjugate purification process.1 There is 
however no mention of specific process residuals such as those used for the oxidation or 
PRP purification steps. Manufacturers differ in the processes used to produce a Hib vaccine. 
This includes a variety of PRP chain lengths, protein carriers, conjugation chemistry and 
purification strategies. It is thus difficult to set specifications that are vaccine and process 
specific and the WHO TRS 897 contains recommendations that are common to all 













4.1.4 Methods of Analysis of Ethylene Glycol 
 
Class 2 solvents are solvents to be limited in use during the production of pharmaceutical 
products. Ethylene glycol is non-volatile and readily miscible with water rendering residual 
solvent determination by headspace analysis not a viable analytical technique. The high 
boiling point of 197.6 °C as well as its relatively high viscosity also limits direct injection onto 
a GC column.  
 
High Performance Liquid Chromatography (HPLC) coupled with a refractive index detector 
can be used for the quantitative analysis of ethylene glycol. The direction and wave velocity 
of light changes when passing from one solution into another. Snell’s law of refraction 
expresses the relationship between the incident angle and the angle of refraction. 
Wavelength of the incident light as well as the density of the medium affects the refractive 
index. Factors such as composition, temperature and pressure in turn affect the density of a 
solution or medium. Refractive index detection in modern refractive index detectors is more 
stable as temperature control for both the reference cell and sample flow cell are very 
accurate. The reference cell takes a “reference” of the mobile phase after equilibration. This 
is achieved by “opening” the reference cell to the flow of mobile phase and then closing after 
stabilisation. The refractive index of the contents of the flow cell is compared to that of the 
mobile phase “reference”. Any changes in the composition of the contents of the flow cell 
would be recorded. The reference cell thus acts as a system blank and for this reason 
chromatography must be isocratic. Reversed phase chromatography using an octadecylsilyl 
column with water as the mobile phase and a refractive index detector has reported 
detection limits for ethylene glycol of 4 mg/l.8, 9 Environmental temperature fluctuations have 
a negative influence on the baseline. Separation is a function of the column as gradient 
elution is not an option.  
 
HPLC using ultraviolet (UV) detection can be used by derivatising ethylene glycol using 
benzoyl chloride. The reaction takes place in an alkaline solution and is terminated by the 
addition of glycine.  Detection limits has been shown to be 10 mg/l with a linear range of 20 
to 2000 mg/l. Cost of solvents used as well as sample preparation time are limitations to the 
method.10 The reaction of ethylene glycol with benzoyl chloride with the subsequent 
extraction of benzoyl esters into a nonpolar solvent yields responses with low detection limits 
using liquid chromatography with either UV detection or electrospray mass spectroscopy 
(ESI-MS). A limit of detection (LOD), for UV detection at 237 nm, of 1 mg/l and limit of 
quantitation (LOQ) of 2 mg/l is listed. The LOD for ESI-MS is listed as 10 – 25 µg/l with a 












The oxidation-reduction reactions of ethylene glycol with sodium periodate yields 
formaldehyde and iodate. The colorimetric determination of formaldehyde using acetyl 
acetone is well known and is described in the European Pharmacopeia as a limit test. The 
reaction of formaldehyde with methylbenzothiazolone hydrazine hydrochloride followed by 
the addition of ferric chloride-sulphamic acid yields a UV active compound with absorbance 
maximum at 628 nm. A calibration curve containing 1.25 µg/ml to 10.0 µg/ml can be 
constructed and ethylene glycol can be indirectly quantified by the quantification of the 
amount of formaldehyde.12   
 
The direct injection of ethylene glycol on to gas chromatographic columns leads to tailing 
peaks and relatively low sensitivity. Derivatisation of ethylene glycol to a volatile compound 
improves the use of gas chromatography using a flame ionisation detector with direct 
injection. Derivatisation can eliminate or minimize tailing and improve sensitivity.  
 
The derivatisation of ethylene glycol with phenylboronic acid produces a cyclic 
phenylboronate ester. It has a linear response over the range of 250 mg/l to 5000 mg/l with 
coefficient of variation less than 2.5%. The detection limit is reported as 10 mg/l and 
recovery as 96%.The derivatisation process is rapid.13 Peak shape is however compromised 
and baseline resolution between peaks can be affected.  
 
Ethylene glycol volatilisation by derivatisation with N, O-bis (trimethylsilyl) trifluoroacetamide: 
trimethylchlorosilane (BSTFA: TMCS) has a detection limit of 5 ppm.4 Peak shape and 
baseline separation of both the analyte and internal standard are acceptable. The addition of 
the internal standard, 3-bromo-1-propanol, to the sample at the beginning of the 
derivatisation process ensures that it undergoes all transfers and reactions the analyte does. 
The acetonitrile used to dissolve the internal standard serves as a means to precipitate 
protein as well.4 The PRP sample is in a buffer solution necessitating moisture removal in 
order to prevent interference with the derivatisation reagent. The addition of the mixture of 
78: 20: 2 2, 2-dimethoxypropane: N, N-dimethylformamide: acetic acid facilitates this. The 
reaction between 2, 2- dimethoxypropane and water forms methanol and acetone using 
glacial acetic acid as a catalyst. The N, N-dimethylformamide “traps” the ethylene glycol 
preventing evaporation when drying the other solvents, methanol, acetone and acetonitrile 















The use of BSTFA (Figure 4.6), instead of BSA yields a highly volatile fluorinated by-product 
after donation of the TMS group. The advantage is that lower molecular weight analytes can 












Figure 4.6 Structure of BSTFA14 
 
The BSTFA by-product is very volatile and elutes early. The presence of fluorine atoms 
causes less flame ionisation detector fouling due to silica deposits. TMCS acts as a catalyst 
driving a faster reaction.14   
 
A nucleophilic attack by the electrons on the hydroxyl group of the analyte on the silicon 
atom of the silylating reagent causes the leaving group, which in this case a fluorinated 





























Figure 4.7 Reaction mechanism of silylating reaction 
 
A limit of detection less than 10 mg/l, with recovery of 91% and intraassay coefficient of 
variation ≤ 2.8% is reported.  Derivatisation is rapid and does not require incubation.4 
Ethylene glycol determination in activated PRP will be based on this procedure and the 













4.2 Experimental  
 
4.2.1 Test Samples 
 Activated PRP batch # X070908, The Biovac Institute. 
 Ethylene glycol, Sigma Aldrich, CAS number 107-21-1 
 
4.2.2 Reagents 
     Acetic acid, Merck, CAS number 64-19-7 
     Acetonitrile, Merck, CAS number 75-05-8 
     3–Bromo-1-propanol, Sigma Aldrich, CAS number 627-18-9 
     BSTFA:TMCS reagent, Supelco 
     2,2-Dimethoxypropane, Sigma Aldrich, CAS number 77-76-9 
     N,N-Dimethylformamide, Sigma Aldrich, CAS number 68-12-2 
 
4.2.3 Equipment 
 Agilent 7890 Gas chromatograph 
 CTC PAL autosampler 
 Reacti-vap/ Reacti-therm sample evaporation unit, Thermo Scientific 
 Eppendorf pipettes, 200 µl, 1000 µl 
 Reacti vials, Thermo Scientific 
 
 
4.2.4 Sample Preparation  
 
The internal standard 3-bromo-1-propanol was prepared by dissolving/ mixing 31.4 µl with 
acetonitrile in a 100 ml volumetric flask.  This equates to a concentration of 0.5 ppm. 
 
Samples were prepared by adding 200 µl of the internal standard solution to 100 µl of the 
sample. The solution was vortexed and to 100 µl of the supernatant added 500 µl of a 
mixture of 7.8: 2.0: 0.2 2, 2-dimethoxypropane: N, N-dimethylformamide: acetic acid. The 
solution was allowed to stand for 5 minutes at room temperature. Excess solvent and 
moisture was removed by drying on a heating block at 60 °C while flushing with nitrogen. 
To a volume of < 50 µl, 100 µl of the BSTFA: TMCS reagent was added and the solution 



















 Heater : 250 °C 
 Mode: Split 
 Split ratio: 20 : 1 
 Total flow: 24 ml/minute 




 Flow rate: 1 ml/minute 




 Equilibration time: 3 minutes 
 Oven Program: 
90 °C hold for 3 minutes 
15 °C/ minute to 170 °C hold for 5 minutes 
20 °C/ minute to 220 °C hold for 4.167 minutes 




 Hydrogen 200 ml/minute 
 Nitrogen   300 ml/minute 


















4.2.6 GC-FID Analysis of Ethylene Glycol 
 





Figure 4.8 Chromatogram of ethylene glycol and the 3-bromo-1-propanol internal standard 
Ethylene glycol elutes at a retention time of ± 7.6 minutes and 3-bromo-1-propanol at  
± 8.2 minutes giving a relative retention time of 1.09 to the main analyte. The elution time is 
relatively short with good baseline separation between peaks. The analyte and internal 
standard have tailing factors of less than 2 indicating peaks approaching a normal or 
Gaussian shape.  Solvent peaks elute early and do not interfere with that of the analyte and 
internal standard.  
 












4.3 RESULTS AND DISCUSSION  
 The suitability of the method to quantify residual ethylene glycol in activated PRP was 
evaluated using current validation practices. Parameters assessed include linearity and 
range, specificity, precision and accuracy.  
4.3.1 Linearity and Range 
 
The linearity was assessed by making up solutions of ethylene glycol in purified water of 
different concentrations ranging from 5 ppm to 500 ppm. The range was determined from the 
linear portion of the graph. 
 
Table 4.1: Results obtained for Linearity and Range study 








5 721154 273083 2.64 
50 1275804 275532 4.63 
100 1845864 217729 8.48 
250 5601834 259564 21.58 





Figure 4.9 Ethylene glycol response vs. concentration 
 
 
The range was found to be linear with a correlation coefficient of 0.998 from a concentration 
of 5 ppm to 500 ppm.  The correlation coefficient of the data set is close to 1 indicating data 
y = 0.0811x + 1.1544 








































points close to the regression line. The y-intercept for the graph is positive resulting in a 
positive response for a 0 ppm solution. The response obtained is however negligible and 
would not have a significant impact on generated results.  
4.3.2 Specificity 
 
Specificity was evaluated by testing a specific volume of PRP polysaccharide spiked with a 
standard of a known concentration of ethylene glycol (125 ppm). The same volumes of 
polysaccharide and standard were tested independently and the ethylene glycol value of 
the” spiked’ polysaccharide compared to the sum of the individual polysaccharide and 
standard solutions. 
 














PRP + Std 2542832 245079 10.38 113.76 
103.14 PRP + H2O 0 221776 0 0 
Std + H2O 2427918 227521 10.67 117.33 
 
 
% Recovery = [(PRP + H2O) + (Std + H2O)]/ (PRP + Std) X 100 
 
The results indicate that the other components present in the polysaccharide do not interfere 
with the ethylene glycol assay. All sample matrix effects can be eliminated based on this. 
The acceptance criterion for accuracy is 90 to 110% of the actual amount and will be applied 




Precision was assessed by analysing an ethylene glycol concentration six times. The  
% RSD was calculated and reported.  A standard solution with concentration within the linear 



























500 9567152 225245 42.4744 
500 9951651 247633 40.1871 
500 11679844 265508 43.9906 
500 9320429 222286 41.9299 
500 9705991 226403 42.8704 
500 9567152 225245 42.4744 
Average 10045013 237415 42.29048 
Standard Deviation 18653.98 18653.98 1.397736 





Figure 4.10 Ethylene glycol precision  
 
Repeated analyses of the same sample yielded a low % RSD. Using the average and 
standard deviation of the analysis of the six samples enabled the calculation of upper and 
lower control limits.  The minimum number of analyses required for plotting a statistical 
process control chart is 10. The value of a control chart is to monitor trends in the production 
processes to enable proactive instead of reactive interventions. Alert limits indicates when a 
process is on route to go out of control, whereas action limits indicates when a process is out 
of control and steps needs to be taken to bring it back to a state of control. Limits for a 
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the same product are manufactured using the same technique, equipment and type of raw 
materials. The control limits of the control chart were calculated from the data generated 
from the precision study as routine production of the Hib vaccine at the Biovac Institute has 
not commenced.  
4.3.4 Accuracy 
 
Accuracy was assessed by the triplicate analyses of 3 different concentrations from the 
lower, middle and upper region of the linear range. The average, standard deviation and  
% RSD of each sample set was determined. 50 ppm, 100 ppm and 500 ppm ethylene glycol 
in purified water were analysed. The result of the 100 ppm solution was treated as the 
“actual” concentration. 









705582 497413 1.42 
686187 456344 1.50 
622361 432373 1.44 
Average 671376.67 462043.33 1.45 
Standard deviation  43542.43 32892.43 0.042 
% RSD 6.49 7.12 2.90 
100 
1233602 428655 2.88 
1307814 441176 2.96 
1526812 494774 3.09 
Average 1356076 454868.33 2.98 
Standard deviation  152446.52 35121.80 0.106 
% RSD 11.24 7.72 3.56 
500 
7365828 497911 14.79 
7633122 490779 15.55 
7579484 507431 14.94 
Average 7526144.67 498707 15.09 
Standard deviation  141404.86 8354.49 0.40 
% RSD 1.88 1.68 2.67 
The response obtained for the 100 ppm concentration was used to calculate the 50 ppm and 
500 ppm % Recovery.  
 













50 ppm = [(1.45 X 2)/ 2.98] X 100 
  = 97.32 % 
 
500 ppm = [(15.09/5)/2.98] X 100 
     = 101.28 % 
 
 
The amount of variance, of the triplicate analyses of the different solutions, was relatively 
low.  The triplicate analysis of the 50 ppm solution yielded a %RSD of 2.90% that of the  
100 ppm solution was 3.56 % while that of the 500 ppm solution was 2.67%. The recoveries 
for the 50 ppm and 500 ppm solution, using the 100 ppm solution as reference, were 97.32% 














4.4 Conclusion  
 
Ethylene glycol is classified as a Class 2 solvent and it is recommended by the USP to limit 
use in production processes.5 The WHO TRS 897 requires evidence of removal of residual 
solvents by either process validation or validated quality control test methods. Ethylene 
glycol was analysed using 3–bromo–1–propanol as an internal standard. The internal 
standard was added prior to sample processing ensuring exposure to the same conditions 
as the analyte. Moisture was removed by using a mixture of 2, 2-dimethoxypropane: N, N- 
dimethylformamide: acetic acid where the reaction with water produces the volatile solvents 
methanol and acetone. The sample was subjected to heat under a constant flow of nitrogen 
on a Reacti–vap/Reacti-therm unit. The derivatisation with the BSTFA: TMCS reagent was 
quick and injection on the HP5 capillary column, installed in a GC-FID, yielded two distinct 
peaks for the analyte and internal standard.   
 
The analysis of ethylene glycol was linear across a range of 5 ppm to 500 ppm with a R2  
value of 0.998.  Specificity was established with a recovery of 97.3%. The % RSD of the 
precision study of a 500 ppm solution was 3.31%. The accuracy study had recoveries for the 
50 ppm solution of 97.32% and for the 500 ppm solution 101.28%.  
 
The method meets all validation acceptance criteria for the linear range. The retention times 
of ethylene glycol and 3–bromo–1–propanol are less than 10 minutes resulting a relatively 
short analysis. This length of analysis together with the use of an autosampler enables 
multiple sample analysis. The method can be implemented in a laboratory for the routine 
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Development and assessment of an assay to determine 
polyribosylribitolphosphate (PRP) 
 
The capsular polysaccharide of Haemophilus influenzae type b (Hib) is conjugated to the 
carrier protein tetanus toxoid for vaccine production at The Biovac Institute. A selective and 
sensitive method is needed to quantify the Hib polysaccharide antigen content. Conjugated 
polysaccharide alone is of immunological importance as potency is directly related to the 
amount of polysaccharide bound to the protein carrier. Colorimetric methods currently 
employed are non-specific and have the risk of being affected by other contributing 
components.  The assay to be investigated is based on a gas chromatography with mass 
selective detector (GC-MS) method applied to pneumococcal conjugate vaccines which 
determines the PRP content and can be applied to both conjugated and “free” PRP.   
 
5.1 Background 
The quantification of PRP in both conjugated and unconjugated form is a requirement for 
both vaccine release testing as well as vaccine stability studies. PRP that is covalently 
bound to the carrier protein is immunologically important. Hib conjugate vaccines should be 
tested for both conjugated and unconjugated PRP against specifications agreed to by the 
national authority which is based on the data from a successful clinical trial.1 See Figure 5.1 
for the relationship between total Hib saccharide content, conjugated and unconjugated 
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The free saccharide content is reported as a percentage of the total saccharide. Vaccines 
with successful clinical trials contained unconjugated polysaccharide quantities of less than 
10 % and up to 40 %.1 Approved Hib vaccines consisting of PRP conjugated to a tetanus 
toxoid carrier protein have free PRP specifications of < 20%.2 
    
Traditional vaccine potency and safety assays are performed in animals. Animal based 
models suffer from inherent variability and there is currently a lack of adequate biological 
assays for evaluating the potency or efficacy of Hib conjugated vaccines. Hib vaccine 
potency and efficacy were evaluated in mice and guinea pigs, but the results generated 
could not be correlated with the immune response of human infants. Animal assays are only 
needed during the vaccine development process in order to show the ability of the vaccine to 
induce a T-cell-dependent response.  Lot release and quality control of Hib vaccines is done 
by the characterisation of the polysaccharide, carrier protein and conjugate by physico- 
chemical means as well as batch-to-batch consistency.1 Quantification of the Hib antigen 
conjugated and unconjugated content, by means of physico-chemical methods, replaces 
traditional animal based potency assays.  
 
Stability studies are done per product, present tion (vial/ syringe, volume, freeze- 
dried/liquid) and continue throughout the lifecycle of the product.2,3  The stability of the 
amount of unconjugated polysaccharide is monitored over time at typical storage conditions.   
This should stay within a predefined acceptance criterion throughout the study. Hydrolysis of 
the phosphodiester bond between the PRP monomers results in an increase in the amount 
of free and or depolymerized PRP. In a multivalent vaccine, containing a Hib vaccine 
component, the rate of this hydrolysis is affected by temperature, adjuvant and divalent 
cation interaction.4 The assay used to determine the amount of polysaccharide should be 
sensitive enough to determine changes in the amount of unconjugated polysaccharide.  
 
5.1.1 The Conjugation Process 
The PRP length, protein carrier and conjugation chemistry of Hib conjugate vaccine varies 
between manufacturers. This study is performed on a Hib vaccine where the PRP is 
conjugated to tetanus toxoid (TT).  
 
The protein carrier has carboxyl groups which are activated by reacting with 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide HCl (EDC) in the presence of adipic acid dihydrazide.  
The activated PRP which is treated with periodate is size-reduced and terminates in an 
aldehyde group on each terminus. Proximity of the electronegative oxygen atoms renders 












catalyst and a nucleophilic attack on the electrophilic PRP carbon takes place. A hydrazone 
derivative is formed which are stabilized after the conjugation process, to a stable acid 




Figure 5.2 Conjugation of PRP with activated tetanus toxoid 
 
The conjugation of the derivatized TT with the activated PRP yields a high molecular weight 
conjugate. Molecular size exclusion chromatography is used to monitor the conjugation 
reaction as well as the quality of the activated PRP and derivatized TT.4,5,6 
 
5.1.2 PRP Specification  
According to the World Health Organisation (WHO) Technical Report Series (TRS) 897, the 
amount of free PRP in conjugated bulk must be verified by validated test methods to ensure 
that it is within limits. These limits are based on batches proven to be clinically safe and 
efficacious. The total PRP content should be within ± 20% of the stated content. Limits of 
free PRP in conjugated bulk and total PRP in the final product must be agreed with the 
national control authority.1 This required a method for PRP quantification and a separation 
technique separating free from conjugated PRP so that it can also be quantified. The free 













5.1.3 PRP Quantification 
The quantification of PRP can be performed directly by determining the concentration of 
ribitolribosephosphate subunits or by determining the concentration of ribitol, ribose or 
phosphate. The polysaccharide is characterised by the ribose and phosphorus content.  
 
The Bial method or orcinol test is used to indirectly determine the amount of PRP. The 
orcinol assay determines the concentration of pentose and in this case D-ribose, an 
aldopentose. The WHO recommends a ribose content of not less than 32% of the 
polysaccharide weight on dry basis.1 The polysaccharide is heated with a mineral acid, 
hydrochloric acid, containing ferric chloride and orcinol.  The pentose forms a green coloured 
complex with the orcinol and ferric chloride. Detection is performed on a spectrophotometer 
at a wavelength of 670 nm. D-ribose is used to construct a calibration curve in order to 
determine concentration.7 This method was evaluated at The Biovac Institute (TBI) and 
linearity was established between 2.0 µg/ml to 40.0 µg/ml with a % relative standard 
deviation (% RSD) of < 2.0%. Accuracy and specificity were determined between 90% to 
100%. The presence of ribonucleic acid (RNA) increases the amount of ribose present in the 
sample. This method has limited application because PRP in multivalent vaccine 
formulations where RNA contamination by whole cell pertussis is present cannot be 
accurately quantified using this method.  
 
PRP can be characterised by the phosphorus content. A phosphorus content of between  
6.8% and 9% calculated on the polysaccharide dry weight is recommended.1 The Chen 
method for the determination of phosphates begins with the mineralisation of samples using 
a mixture of sulfuric and perchloric acid which yields inorganic phosphate.  This is performed 
on a heating block capable of temperatures of up to 250 °C. A phosphomolybdate complex 
is formed with ammonium molybdate which after reduction with ascorbic acid provides a blue 
colour. Absorbance can be measured on a spectrophotometer at 825 nm. In order to 
eliminate the contribution of inorganic phosphate in the sample matrix, “free” phosphate is 
determined in a similar manner. The mineralisation step is omitted. The amount of PRP can 
be calculated after the determination of the amount of organic phosphate.8 
 
Organic phosphate  = Total phosphate – Inorganic phosphate 
 
Linearity was established in the quality control (QC) department of TBI between 7.5 µg/ml to 
60.0 µg/ml with an intermediate precision % RSD of < 2.0%.  Accuracy and specificity were 












per the Ames method where magnesium nitrate is used in conjunction with a high 
temperature oven to ash the sample. The colorimetric test follows the same route as the 
Chen method in that a complex with ammonium molybdate is reduced with ascorbic acid 
providing a blue colour. Absorbance is measured on a spectrophotometer at 820 nm. The 
free or inorganic phosphate is determined by omitting the ashing step.9 The determination of 
phosphate by either the Chen or Ames method have to accommodate for inorganic 
phosphate in order to accurately determine the amount of PRP present. Formulations 
involving phosphate buffers can have elevated responses if the inorganic component is not 
accurately quantified.  
 
Nuclear magnetic resonance (NMR) spectroscopy is used for the identification of the 
polysaccharide components of conjugate vaccines.10 It is used to identify impurities, show 
degradation pathways as well as characterising intermediates during the manufacturing 
process. Quantitative analysis of the capsular polysaccharide: protein ratio of Hib using NMR 
has been evaluated, but not validated.11 NMR is not routinely used in a commercial 
manufacturing site due to cost of equipment as well as operational costs. A high level of 
expertise is required to operate the instrument and interpret the data generated.11,12 NMR 
does however not require the use of reference material as is the case with most other wet 
chemical, colorimetric or chromatographic analysis. Impurity isolation is not necessary and 
the analysis could be less time consuming than others.13  
 
The interaction between Hib antibody and polysaccharide antigen enables the use of 
enzyme-linked immunoabsorbant assays (ELISA) for the qualitative analysis of Hib.14 
Quantitative ELISA analysis of Hib vaccines can also be performed. Concentrations between 
0.04 µg/ml and 30 µg/ml purified polysaccharide are used to coat the chemically modified 
micro well plates. The coated plate is washed with a phosphate buffer solution and Tween 
20 where after it is blocked with goat serum. Sera diluted with phosphate buffer and goat 
serum is added. Goat antihuman IgG coupled to peroxidase is added which bonds to the 
goat serum. The ELISA plate is incubated after the addition of a solution of o-
phenylenediamine dihydrochloride in a citrate buffer mixed with hydrogen peroxide. 1M 
sulfuric acid stops the reaction and the absorbance is read at a wavelength of 492 nm. Intra- 
assay and inter-assay variation has Coefficient of Variation (% CV) of 1.1 % and 5.2 % 
respectively. Optimal coating of the ELISA plate is achieved at 1 µg/ml.15  Direct coating of 
ELISA plates with polysaccharide have poor reproducibility and modification of the 
polysaccharide is required. The polysaccharide is often conjugated to a molecule more 
suited for binding to the ELISA plate. This alteration of the structure of the polysaccharide by 












always available. Hib vaccines consist of a heterogeneous mixture of conjugated and free 
polysaccharide of different lengths. Antigen antibody interaction of ELISA-based techniques 
can suffer interference due to size chain length variation of the polysaccharide.  
 
The depolymerisation of the PRP polysaccharide followed by chromatographic analysis is 
selective and sensitive. Commercially available reference standards can be used to 
construct calibration curves for quantification of the analyte. Chromatography can be 
performed on native or derivatised analytes. Methods able to quantify nonderivatised 
carbohydrates at picomole levels are available.16  
 
High-performance anion-exchange chromatography with pulsed amperometric detection 
(HPAEC-PAD) allows low level quantification of nonderivatised carbohydrates. Hydrolysis of 
the polysaccharide in Hib vaccine using base yields the ribitolribosephosphate subunit which 
can be directly quantified.16 Base hydrolysis of Hib when in combination with diphtheria, 
pertussis and tetanus (DPT) leads to the elution of a peak coinciding with that of the Hib 
subunit. Hydrolysis using trifluoroacetic acid (TFA) releases ribitol which elutes with baseline 
separation from other peaks. A linear response of the ribitol standard from 0.15 µg/ml to 2.5 
µg/ml as well as repeatability with %CV < 5% is achieved.16  
TFA hydrolysis can be long and the alkaline mobile phase is relatively harsh on components. 
Running costs of the equipment are expensive. Baseline separation of peaks is not always 
achieved and column deterioration due to sample matrix effects is rapid.  
Hydrolysis of covalently linked carbohydrates such as PRP-TT, results in the formation of 
monosaccharides. The monosaccharides are analysed to quantify the amount of 
polysaccharides. Conventional methods of hydrolysis make use of either an aqueous acid or 
base. In contrast the methanolysis of carbohydrates yields stable methyl glycosides of the 
constituent monosaccharides. The process causes less destruction of the carbohydrate 
when compared to aqueous acid hydrolysis.17  
 
A quantitative analysis using gas chromatography with a mass selective detector has been 
applied to pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7V, 9V, 14, 18C, 19A, 19F and 23F 
polysaccharides or conjugates. 18  Polysaccharides are subjected to anhydrous methanolysis 
with methanolic hydrochloric acid (HCl) and relatively stable methyl glycosides are formed. 
Derivatisation of the methyl glycosides by a silylating agent renders it volatile and the sample 
dissolved in a suitable solvent can be analysed on the GC. Gas chromatography provides 
good baseline separation or resolution; high efficiency or plate count and identification of 
peaks can be evaluated if combined with a mass selective detector. Pneumococcal vaccine 












serotypes 6A and 6B result in the release of two forms of ribitol, a ring-form 1, 4 - 
anhydroribitol and ribitol.18 Acid treatment of ribitol has been known to convert to 1, 4 - 
anhydroribitol.19 Quantification of serotypes 6A and 6B are performed by using the response 
for both forms of ribitol.18 Methanolysis has the advantage over aqueous acid hydrolysis in 
that it causes less destruction of carbohydrate.17,20 The presence of moisture in methanolic 
HCl of more than 2% results in a decrease in methyl glycoside formation. Trimethylsilylation 
is also sensitive to the presence of moisture and concentrations of more than and equal to 
0.2% v/v can result in a considerable loss of monosaccharide.17  Silylating agents replaces 
the active hydrogen in the molecule effectively reducing polarity and hydrogen bonding. The 
silylating agent used is based on the procedure of Sweeley et al. A mixture of 
HMDS:TMCS:pyridine (3:1:9) reacts better than the individual silylating components.20,21 See 
Figure 5.3 for the reaction mechanism. The nucleophilic attack on the silicon atom forms a 
reversible transition group. The reaction is pushed forward as a result of the basicity of the 
leaving group. The proton affinity of the leaving group enables the formation of the stable 













Sample O SiH CH3
CH3
CH3
+   HX
For HDMS, X = NHSi(CH3)3
 For TMCS, X = Cl
For pyridine X = C5H5N
Figure 5.3 Derivatisation reaction mechanism 21 
 
5.1.4 Free Polysaccharide Separation 
In order to quantify the amount of free saccharide, the saccharide conjugated to the carrier 
protein needs to be separated from the free.  
 
PRP-OMPC (meningococcal outer-membrane protein complex high in molecular weight) is a 
conjugate Hib vaccine consisting of an oligosaccharide and a large protein. Quantification of 
the Hib vaccine was performed in a multivalent vaccine consisting of polio, pertussis, 
diphtheria, tetanus and hepatitis B. Passive adsorption of PRP to the aluminium adjuvant in 
combination vaccines was eliminated by using a dissolution buffer consisting of sodium 
hydroxide and sodium citrate. It was subjected to ultracentrifugation in order to separate the 
conjugated PRP from the unconjugated PRP.  Ultracentrifugation was performed at 475 000 












PRP was filtered through a molecular weight cut-off (MWCO) membrane microfilter of 
10 000 MWCO in order to remove protein. PRP content was determined using          
HPAEC-PAD. A recovery bias of less than 5 % was reported when applied to PRP-OMPC in 
both monovalent and multivalent vaccines.4   
 
A Hib vaccine consisting of PRP oligosaccharides conjugated to the carrier protein 
diphtheria CRM197 was analysed for total and free PRP content. The PRP content was 
evaluated in both monovalent and multivalent vaccine where the multivalent vaccine 
consisted of diphtheria, pertussis, tetanus (DPT). Analytical ultrafiltration was used to 
separate the conjugated PRP from the unconjugated. Ultrafiltration of the sample was 
performed using a cellulose membrane with a cut-off of 30 kDa. The filter was centrifuged for 
30 minutes at 3000 rpm and washed with a saline solution. Recoveries between 80% and 
110% for PRP, PRP conjugated to a protein carrier and also Hib as part of a combination 
vaccine was reported. This separation method was evaluated for oligosaccharide based 
conjugates 16 
PRP conjugated to tetanus toxoid carrier protein was analysed for total and free PRP 
content by HPAEC-PAD. The conjugated PRP was precipitated from the solution using 
deoxycholic acid (DOC) sodium salt. A volume of 100 µl of a 1% DOC solution is added to 1 
ml sample, incubated in ice for 30 minutes. The pH is adjusted by adding 50 µl 1 M 
hydrochloric acid after which it is centrifuged. The supernatant is removed in order to 
analyse the free saccharide. A recovery of more than 90 % at a pH of 6.8 is listed for this 
procedure. Conjugate precipitation is listed as 100% while recovery of PRP 96%.22  
 
5.1.5 Method of Analysis for PRP-TT 
The Hib polysaccharide will be subjected to methanolysis in order to form stable methyl 
glycosides. Trimethylsilylating will then be performed rendering volatile complexes for 
analysis.  A gas chromatography with flame ionisation detection (GC-FID) method based on 
that used for pneumococcal vaccine serotypes 6A and 6B will be evaluated for use in Hib 
quality control. Chromatography on a GC using capillary columns has the advantage of 
providing good separation and derivatized samples are relatively clean.  Low level detection 
would enable analysis of Hib in either formulated bulk or as a final product. Determining the 
amount of PRP by means of quantifying ribitol has the added advantage of lacking 
interference by other vaccine components. Ribose and phosphate cannot accurately be 
determined in combination vaccines due to contributing factors like the presence of 
deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). A GC-FID is a relatively common 












saccharide separation will be done by DOC precipitation as it is a technique verified in the 
Research and Development department (R&D) of The Biovac Institute (TBI).   
 
5.2 Experimental  
5.2.1 Test Samples 
 Purified PRP batch # P90, P41 The Biovac Institute. 
 Conjugate batch # C170109, The Biovac Institute 
 Ribitol, Sigma Aldrich, CAS number 488-81-3  
 Myo-inositol, Sigma Aldrich, CAS number 87-89-8 
 
5.2.2 Reagents 
 n - Hexane, Merck, CAS number 110-54-3 
 Methanol, Merck, CAS number 67-56-1 
 3 N Methanolic HCl, Sigma, CAS number 7647-01-0 
 Sweeley reagent (HMDS:TMCS:pyridine, 3:1:9) , Supelco, CAS number 318974-69-5 
    Deoxycholic acid sodium salt, Sigma Aldrich, CAS number 302-95-4 
 
5.2.3 Equipment 
 Agilent 7890 Gas chromatograph 
 CTC PAL autosampler 
 Reacti-vap/ Reacti-therm sample evaporation unit, Thermo Scientific 
 Virtis bench top freeze drier 
 Eppendorf pipettes, 200 µl, 1000 µl 
 Reacti vials, Thermo Scientific 
 





 Heater : 250 °C 
 Mode:Split 
 Split ratio: 5 : 1 
 Total flow: 9 ml/minute 
















 Flow rate: 1 ml/minute 




 Equilibration time: 3 minutes 
 Oven Program: 
50 °C hold for 3 minutes 
15 °C/ minute to 170 °C  
30 °C/ minute to 220 °C hold for 4.167 minutes 
Run Time 30 minute 
Detector unit: 
 
 Hydrogen 200 ml/minute 
 Nitrogen   300 ml/minute 
 Air            400 ml/minute 
Column 
 
J&W Scientific, HP 5 column, 30 metres X 0.320 millimetres X 0.25 micrometres 
 
5.2.5 Standard Preparation  
Two sets of standards were prepared, a set ranging from 0.25 µg/ml to 30 µg/ml and a set 
ranging from 0.01 mg/ml to 1.0 mg/ml. A myo-inositol stock solution of 1 mg/ml was 
prepared in purified water. A further 1:10 dilution was made giving a working solution of 
concentration 100 µg/ml. The ribitol standard was prepared in a similar manner by making a 
stock solution of 1 mg/ml. A further 1:10 dilution was made to give a 100 µg/ml solution.  
Standard solutions were prepared in volumetric flasks by using a micro pipette then adding 
the required volume of the ribitol solutions. The internal standard was added thereafter and 
the solution diluted to the correct volume with purified water.  
 
5.2.6 Sample Preparation 
Samples were prepared by diluting the PRP and conjugate samples to within concentration 
ranges of 0.5 µg/ml to 30 µg/ml and 0.01 mg/ml to 1.0 mg/ml ribitol. Sample concentrations 
were based on colorimetric assays as per the Bial method assessed by the R&D department 















5.2.7 Freeze Drying 
A volume of 1.0 ml of each sample to be analysed was added to separate Reacti-vials, 
sealed with parafilm and frozen. In order to remove moisture, the frozen samples were dried 
by lyophilisation. The water undergoes sublimation, thus moving from the solid phase to the 




Methanolysis was performed on all samples containing polysaccharide. The polysaccharide 
was hydrolysed into monomers through methanolysis with 3 N methanolic HCl. This step 
took place on a heating block at 80 °C for 2 hours.  Samples were dried on the Reacti- 
vap/Reacti-therm unit at 40 °C using instrument grade nitrogen. In order to remove excess 
hydrochloric acid (HCl) from the samples, 120 µl methanol was used to rinse the vials. The 
solvent was evaporated after the rinsing. This washing of the residue with methanol was 
repeated 3 times.  
 
5.2.9 Derivatisation 
Derivatisation of the analyte was performed by adding 200 µl Sweeley reagent and 
incubating at 80 °C on a heating block for 20 minutes. The silylating reagent was added in 
excess. The solvent was dried off using nitrogen gas on the Reacti-vap/Reacti-therm unit 
and the analyte was dissolved in 250 µl n-hexane prior to injection. See Figure 5.4 for the 
flow diagram of the sample preparation process. The ribitol standards were freeze dried and 
derivatized only. The methanolysis step was omitted. 
 
Care was taken to minimize moisture throughout the methanolysis and derivatisation 
process. The nitrogen gas was subjected to drying over silicon crystals prior to contact with 
the sample. Sweeley reagent was stored in a sealed desiccator over silicon drying crystals. 
Methanolic HCl was capped and sealed with parafilm. Both reagents were stored in a fridge 














Figure 5.4 Flow diagram of sample preparation 
5.2.10 Analysis 
Analysis of a ribitol standard solution containing the myo–inositol internal standard yields 
distinct, well resolved peaks. Ribitol elutes at a retention time of ± 16 minutes and myo- 
inositol ± 26 minutes giving a relative retention time of 1.62 to the main analyte. The internal 
standard was added before freeze drying and was subjected to the same conditions as the 
analyte. Injector reproducibility as well as losses during sample preparation can be 
accounted for. 
 



























The analyte and internal standard have tailing factors of less than 2 indicating peaks 
approaching a normal or Gaussian shape.  Solvent peaks elute early and do not interfere 
with that of the analyte and internal standard. Methanolysis yields ribitol in a ring structure 
anhydro form as well.  The anhydro form elutes earlier than the main peak with an elution 
time of ± 11 minutes and a RRT of 0.72. See Figure 5.6 for a chromatograph of the 1, 4 - 
anhydroribitol peak after methanolysis of a ribitol standard solution and Figure 5.7 after 
























Figure 5.6 Chromatogram of derivatized PRP 
 
Figure 5.7 Chromatogram of derivatised PRP 














Quantification of PRP was performed by combining the response for ribitol and 1, 4 - 
anhydroribitol. This was performed in accordance with the method of quantification for 
pneumococcal serotypes 6A and 6B.20 
 
5.3 Results and Discussion 
This study evaluates the development of a GC-FID method for the determination of PRP 
content using validation principles.  
 
5.3.1 Linearity  
The linearity was assessed by making up solutions of ribitol in purified water of different 
concentrations ranging from 0.25 µg/ml to 30 µg/ml with internal standard concentrations of 
10.0 µg/ml.   
 









Internal Standard Corrected 
Response 
0.25 14639 595727 0.024573 
0.5 33929 690419 0.049143 
1.0 70129 699040 0.100322 
5.0 323420 716601 0.451325 
10.0 549775 769408 0.714543 
20.0 1438191 751738 1.913155 




Figure 5.8 Calibration curve of lower concentration ribitol standards 
y = 0.0983x - 0.0468 








































The range was found to be linear with a correlation coefficient of 0.9921 from a 
concentration of 0.25 µg/ml to 30 µg/ml. The y-intercept for the graph was negative, but it 
approaches zero and will have a negligible effect on the data. A larger negative value would 
yield a large negative for the blank value. This is typical of a method not sensitive enough or 
interference by the blank on the response.  
Linearity was also evaluated at a higher concentration of 0.01 mg/ml to 1 mg/ml with an 
internal standard concentration of 50 µg/ml. 
 









Internal Standard Corrected 
Response 
0.01 554794 2909820 0.190663 
0.05 2925459 3093531 0.945670 
0.2 13911579 3464041 4.016000 
0.5 32282380 3780446 8.539305 




Figure 5.9 Calibration curve of higher ribitol standards concentration 
 
The range was found to be linear with a correlation coefficient of 0.9937 from a 
concentration of 0.1 mg/ml to 1.0 mg/ml. The y-intercept for the graph was positive indicating 
that the blank would have a positive response.  Blank subtraction of all data points will 
eliminate this and shift the graph through zero.  
 
 
y = 15.048x + 0.4741 








































The experiment was repeated using PRP diluted in purified water of concentrations  
0.9 µg/ml to 27.7 µg/ml and internal standard concentration of 5.0 µg/ml.  
 








Internal Standard Corrected 
Response 
0.92 51733 398378 0.129859 
2.31 78522 385074 0.203914 
4.61 138139 391998 0.352397 
6.92 117401 259757 0.451965 
9.22 180750 280613 0.644126 
13.83 292617 317313 0.922171 




Figure 5.10 PRP response vs. concentration 
 
The y-intercept in this case was positive and would lead to a positive result for a blank 
solution. Blank subtraction was needed in order to minimize this increased response.   
 
5.3.2 Specificity 
The specificity of the PRP assay was evaluated by testing a concentration of 6.8 µg/ml 
conjugate (PRP-TT) spiked with 5.9 µg/ml polysaccharide with internal standard 
concentration of 10.0 µg/ml. The conjugate and polysaccharide components of the spiked 
solution were also analysed separately. The ribitol response was compared to that of a      
10 µg/ml ribitol standard containing a 10 µg/ml myo inositol internal standard.  
y = 0.0693x + 0.017 

















































449844 1826912 0.246232 2.46 
404232 1597842 0.252986 2.53 
364285 1613992 0.225704 2.26 
Average 406120.3 1679582 0.241641 2.42 
Stdev 42810.75 127846.8 0.014209 0.14 
%RSD 10.54139 7.611822 5.88004 5.79 
Polysaccharide 
413685 1528762 0.270601 2.71 
399090 1385649 0.288017 2.88 
366482 1453550 0.252129 2.52 
Average 393085.7 1455987 0.270249 2.70 
Stdev 24167.54 71587.62 0.017946 0.18 
%RSD 6.14816 4.916776 6.640715 6.70 
Spiked solution 
434556 809125 0.537069 5.37 
844260 1572115 0.537022 5.37 
889972 1611625 0.55222 5.52 
Average 722929.3 1330955 0.542104 5.42 
Stdev 250782.3 452349.6 0.008761 0.087 
%RSD 34.68974 33.98684 1.616155 1.61 
 
The analysis of the first spike solution have a response for both ribitol and myo - inositol that 
is more or less half that of the remaining two analysis. The analyte response is corrected 
with that of the internal standard yielding a response similar to the second and third analysis.  
Polysaccharide content was calculated by multiplying the ribitol concentration by a factor of 
2.45. The factor was determined from the molecular weight of ribitol and that of a single 
polysaccharide repeating unit.   
 
The average corrected response for the 10 µg/ml ribitol standard was 1.01 and was used to 
calculate the response above.  
Sample concentration = (Ribitol standard concentration X Sample response) 













The average PRP concentration of the conjugate sample was calculated as 5.93 µg/ml 
representing an 87.2% yield.  The average concentration of the PRP sample was calculated 
as 6.62 µg/ml representing a 112.2 % yield. The spiked solution has a PRP concentration of 
13.28 µg/ml.  This corresponds to a 104.6 % yield when compared to the results based on 
the ribose assay. A comparison of the individual solutions and the spiked shows a recovery 
of 94.5 %. This was calculated as follows: 
 
%Recovery = ([conjugate] + [PRP]) / [conjugate + PRP] X 100 
 
Specificity was further assessed by spiking a 10 µg/ml ribitol standard with 6.8 µg/ml 
conjugate. The response for the spiked solution was compared against that of the individual 
components. The internal standard concentration was 10 µg/ml. 
 













407075 1462983 0.27825 2.7825 
390003 1451593 0.268672 2.6867 
374761 1392342 0.269159 2.6916 
Average 390613 1435639 0.272027 2.7203 
Stdev 16165.63 37926.6 0.005395 0.05395 
%RSD 4.138529 2.641792 1.983152 1.983152 
Ribitol Standard 
1783255 1609151 1.108196 11.0896 
1722232 1575491 1.09314 10.9314 
1888996 1736716 1.087683 10.8768 
Average 1798161 1640453 1.09634 10.9634 
Stdev 84375.35 85048.34 0.010624 0.10624 
%RSD 4.692313 5.184444 0.969085 0.969085 
Spiked solution 
1874099 1411143 1.328072 13.28072 
1903762 1452906 1.310313 13.10313 
1887077 1452119 1.299533 12.99533 
Average 1888313 1438723 1.312639 13.12639 
Stdev 14870.06 23887.93 0.014411 0.144107 













The results indicate that the other components present do not interfere with the assay. All 
sample matrix effects can be eliminated based on this. 
 
5.3.3 Precision 
Precision was assessed by the analyses of 6 aliquots of the same sample using the same 
analyst, reagents and equipment. Ribitol solutions of 5 µg/ml and 0.2 mg/ml and a PRP 
solution of 20 µg/ml were used. The internal standard concentrations were 10 µg/ml and 50 
µg/ml myo–inositol for the ribitol solutions and 20 µg/ml for the PRP solution.  The average, 
standard deviation and % RSD of each sample set was determined.  
 







5.0 250481 544208 0.460267 
5.0 326490 718808 0.454210 
5.0 347004 774489 0.448043 
5.0 278353 677601 0.410792 
5.0 351628 680033 0.517075 
5.0 348166 723302 0.481356 
Average 317020.33 686406.83 0.461957 
Stdev 42612.40 78113.04 0.035465 





Figure 5.11 Ribitol precision 5.0 µg/ml  
 


















































0.2 16212481 3890924 4.166743 
0.2 14882216 3451007 4.312427 
0.2 11136087 2680798 4.154019 
0.2 13791087 3357589 4.107438 
0.2 15474688 3768828 4.105968 
0.2 13529939 3304181 4.094794 
Average 14171083 3408887.833 4.156898 
Stdev 1796611.546 426004.6268 0.081476 





Figure 5.12 Ribitol precision 0.2 mg/ml 
 






















































20 4013177 8024147 0.500138 
20 3844254 7797555 0.493008 
20 3495964 8389597 0.416702 
20 4097227 8085140 0.50676 
20 3962510 8413781 0.470955 
20 120928 207006 0.584176 
Average 3255677 6819538 0.49529 
Stdev 1549996 3247818 0.05446 




Figure 5.13 PRP precision study 
 
Repeated analysis of the same sample yielded a % RSD < 11.  
There was a significant difference in response between analysis of the sixth PRP sample 
and the rest. The response for the analyte, ribitol and the internal standard, myo–inositol was 
considerably less. The significance of the internal standard is illustrated here as the 
response for both decreased proportionally. The corrected response for the analyte however 
differs significantly from that of the other PRP samples. This value was discarded and 
















































Statistical process control charts requires ten points for plotting action and alert limits. The 
precision study was performed in accordance with the ICH Q2 R1 guideline and only six 
replicates were analysed.24 Control limits were calculated using the average and standard 
deviation of the six analyses.  
 
5.3.4 Accuracy 
Accuracy was assessed by the triplicate analyses of 3 different concentrations from the 
lower, middle and upper region of the linear range. The average, standard deviation and 
%RSD of each sample set was determined. 0.5 µg/ml, 5 µg/ml and 20 µg/ml ribitol in purified 
water were analysed. The internal standard concentration was 10.0 µg/ml. The result of the 
5 µg/ml solution was treated as the “actual” concentration. 
 
Table 5.9: Results obtained for accuracy study 
Concentration 
(µg/ml) 





35101 673608 0.052108942 
33634 636747 0.052821607 
33052 760903 0.043437863 
Average 33929 690419.3333 0.049456137 
Stdev  1055.873572 63762.40099 0.005224145 
% RSD 3.112009113 9.235315107 10.56318923 
 
5.0 
345346 720948 0.479016517 
322645 779383 0.413974901 
321368 676903 0.474762263 
Average 329786.3333 725744.6667 0.455917894 
Stdev  13490.18541 51408.10839 0.036385927 
% RSD 4.090583522 7.083497923 7.980806891 
    
20.0 
1350336 669744 2.016197234 
1442974 732930 1.968774644 
1521265 852542 1.784387162 
Average 1438191.667 751738.6667 1.92311968 
Stdev  85564.79296 92839.11706 0.122463297 













The response obtained for the 5 µg/ml concentration was used to calculate the 0.5 µg/ml 
and 20.0 µg/ml % Recovery.  
 
% Recovery = (Actual/ Theoretical) X 100% 
 
0.5 µg/ml = [(0.0495 X 10)/ 0.456] X 100 
= 108.55 % 
 
20.0 µg/ml = [(1.92/4)/0.456] X 100 
   = 105.26 % 
 
The triplicate analysis of the 0.5 µg/ml solution yielded a %RSD of 10.56% that of the 5.0 
µg/ml solution was 7.98 % while that of the 20 µg/ml solution was 6.37%. The %RSD’s for 
the triplicate analysis of the three standards decreased with an increase in concentration. 
The values obtained for the lower concentrations correlates with those obtained for the 
precision study in section 5.3.3. The recoveries for the 0.5 µg/ml and 20.0 µg/ml solutions, 
using the 5.0 µg/ml solution as reference, were 108.55% and 105.26% respectively. The 













In order to determine the effect of incubation time on the analyte a PRP sample was 
subjected to methanolysis over different time periods. Variation of incubation time during 
derivatisation was also evaluated. In addition the washing of the sample post methanolysis 
was investigated.  
 
Derivatisation incubation time did not have a significant impact on the analyte response. 
Washing with methanol was a critical step as a reduction in the amount of methanol or the 
number of washing steps resulted in the formation of white precipitation. Yields of both the 
internal standard and ribitol were low.  




Figure 5.14 Relationship between response and incubation 
 
Incubation temperature was kept constant at 80 °C throughout The sample analysed, PRP 
batch P41, was prepared at a concentration of 225 µg/ml P41 and 50 µg/ml myo-inositol. 
Increased incubation time resulted in an increase in the formation of 1, 4 -anhydroribitol. The 
total response for ribitol however remained more or less constant. This corresponds to 
reports in literature where acid treatment of ribitol resulted in conversion of ribitol to 1, 4 -













5.3.6 Free Polysaccharide Quantification 
The quantification of free PRP in Hib conjugate vaccine was established in the R&D 
department, at TBI, using colorimetric assays. DOC precipitation was used to separate 
conjugated from free PRP. The ability of the GC-FID method to detect free saccharide after 
DOC precipitation was evaluated. A solution of conjugate with concentration ± 80 µg/ml was 
spiked with 5.9 µg/ml polysaccharide. Precipitation using 1.0 ml of the solution was 
performed with a 10 µg/ml deoxycholic acid sodium salt (DOC) solution adjusted to pH 6.8 
with 1M hydrochloric acid (HCl). A volume of 50 µl 1M HCl was added after 30 minute 
incubation at 2 °C – 8 °C. The supernatant was removed after centrifugation. To 1.0 ml of 
the supernatant added 1.0 ml of 10 µg/ml internal standard and analysed. Quantification was 
performed by comparison with a 10 µg/ml ribitol standard containing 10 µg/ml internal 
standard. 













491854 1294671 0.3799066 3.799 
428796 1298281 0.3302798 3.303 
Average 460325 1296476 0.3550932 3.551 
Stdev 44588.74 2552.655 0.0350914 0.351 
%RSD 9.686361 0.196892 9.8823101 9.882 
Polysaccharide 
431476 1572892 0.2743202 2.743 
444528 1503871 0.2955892 2.956 
440424 1537258 0.2864997 2.865 
Average 438809.3 1538007 0.2854697 2.855 
Stdev 6674.132 34516.6 0.0106719 0.107 
%RSD 1.520964 2.244242 3.7383491 3.738 
 
 
The % free saccharide for the conjugate was determined as 1.01% equating to 0.81 µg/ml 
ribitol.  
Recovery was calculated by: [Polysaccharide]  X 100 = 104.2% 
 [Spiked] - [Free] 
 
The recovery for the free saccharide quantitation was 104.2%. This illustrates that the      












5.4 Conclusion  
Methanolysis of the Hib polysaccharide using 3N methanolic HCL at 80 °C for 2 hours was 
sufficient to release ribitol and minimize the formation of 1, 4 -anhydroribitol. Myo-inositol 
was used as an internal standard as it is readily available, easily dissolved in water and was 
stable throughout the sample preparation process. The internal standard was added before 
freeze drying and was subjected to the same conditions as the analyte. Injector 
reproducibility as well as losses during sample preparation could be accounted for. 
 
Washing of the sample after methanolysis and drying using pure, dry nitrogen was shown to 
be a critical step prior to derivatisation. The silylating agent reacts with excess methanol and 
moisture thus drying using moisture free nitrogen prevents loss in yield. 
 
Methanolysis of the polysaccharide yielded the 1, 4 -anhydroribitol derivative in varying 
quantities and was accounted for by adding the response to that of the ribitol response. The 
1, 4 -anhydroribitol derivative was identified by subjecting a ribitol standard to methanolysis.  
Subsequent analysis yielded an additional peak in the chromatogram of the ribitol standard 
with a relative retention time of ± 0.72 to the ribitol peak. The total response for the two 
peaks, in the chromatogram of the ribitol sample subjected to methanolysis, equalled that of 
the ribitol sample not subjected to methanolysis. Prolonged methanolysis of PRP resulted in 
an increase in response of this peak and a proportionate decrease in response for ribitol. 
This observation corresponds to that listed in literature. 19, 20, 24 
 
The analysis was linear from a lower concentration of 0.25 µg/ml to 30.0 µg/ml with a R2 
value of 0.9921 and at a higher concentration of 0.01 mg/ml to 1 mg/ml with a R2 value of 
0.9937. A linear curve was also constructed using concentrations of PRP ranging from    
0.92 µg/ml to 18.4 µg/ml resulting in a R2 value of 0.9944. Spike recovery experiments were 
conducted using both ribitol and PRP. Recoveries varied from 87.2% to 112.2%. Precision 
was determined using a 5 µg/ml and a 0.2 mg/ml ribitol solution. The % RSD’s were 7.68% 
and 1.96% respectively. Precision was also evaluated using a 20 µg/ml PRP solution giving 
a % RSD of 11.0%.  
 
Quantification of both total and free PRP is possible. The response for both the 1, 4 - 
anhydroribitol and ribitol were used. Sample preparation is relatively long as the freeze 
drying process is lengthy. Methanolysis and derivatisation takes a considerable amount of 
time as well. The analysis of PRP, using ribitol as a standard, by means of GC-FID is 












the analysis of multiple samples. The GC-FID is a conventional equipment item in the 
pharmaceutical industry and the expense of maintenance as well consumables are relatively 
low. Standards used to generate calibration curves are readily available. All the reagents 
used are commercially available removing the need for in-house preparation. The 
derivatisation reagent is commercially available in 1.0 ml glass ampoules which allows for a 
single use approach eliminating the possibility of moisture contamination due to storage.  
 
The analysis is based on a method developed for the qualitative and quantitative analysis of 
pneumococcal vaccines using GC-MS. The use of mass spectroscopy enables the 
quantification of lower levels of analyte. The GC-FID analysis is however suitable for the 
analysis of Hib as a monovalent vaccine as ribitol concentrations as low as 0.25 µg/ml can 
be quantified. The analysis of Hib, as a component of a multivalent vaccine, using this 
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Quantitative assays were developed for the quality control of the Hib manufacturing process. 
The chromatographic methods made use of a conventional gas chromatograph with flame 
ionisation detection (GC-FID) and using a CTC PAL combination autosampler/headspace 
sampler as the injector. Internal standards were used to accommodate for losses during 
sample preparation as well as that due to possible lack of injector reproducibility. The 
development was performed using current analytical method validation practices.  
The headspace analysis of volatile residuals in pharmaceuticals using a GC-FID is a well-
established technique. Residual ethanol analysis using iso-propanol as the internal standard 
were evaluated for application in bulk purified polyribosylribitolphosphate (PRP). Sodium 
sulfate was used to increase the availability of the analyte and internal standard in the 
headspace of the vial. Chromatograms generated yielded baseline separation with a United 
States Pharmacopoeial (USP) calculated resolution of more than 2.0 and peaks with little 
tailing or fronting. Analysis of the samples using a J&W Scientific DB 624 capillary column 
generated validation data within acceptable levels. The results generated were accurate, 
precise and specific for the analyte and can be implemented in routine quality control of bulk 
purified PRP. 
A GC-FID direct injection method was developed to determine ethylene glycol in activated 
PRP. An internal standard, 3-bromo-1-propanol, was added prior to removal of moisture with 
a mixture of 2, 2-dimethoxypropane: N, N-dimethylformamide: acetic acid. The reaction 
between water and 2, 2-dimethoxypropane, while using acetic acid as the catalyst, resulted 
in the formation of methanol and acetone. N, N-dimethylformamide acted as a trap 
preventing the loss of ethylene glycol when drying. A commercially available drying and 
heating unit, React-vap/Reacti-therm unit, was used to reduce the volume of the samples 
through the evaporation of the volatile acetone and methanol components. Mild heating and 
dry nitrogen gas were used to aid evaporation. The derivatisation was performed using 
BSTFA: TMCS and samples were injected via the direct injection autosampler into the 
injection port.  The sample preparation was relatively short and the analysis using a J&W 
Scientific HP5 capillary column was selective, precise and accurate.  
The analysis of PRP was performed using methanolic hydrochloric acid to generate stable 
methyl glycosides through methanolysis. Derivatisation was performed using a 












vap/Reacti-therm unit. The test method was applied to the quantification of total and 
unconjugated Hib polysaccharide. Quantification was performed by taking into account the 
response for ribitol and 1, 4 –anhydroribitol. The linear range was established using ribitol 
standard solutions. Quantification of PRP was performed in both purified bulk and conjugate 
bulk. The analytical test procedure provided accurate and specific results. The ability to 
detect the polysaccharide after precipitation with deoxycholic acid was evaluated. A spike 
recovery experiment yielded accurate results. The application of this technique to the 
analysis of a multivalent vaccine should be evaluated in future. In addition, the method of 
analysis should be expanded by using a GC-MS.  Detection limits of a GC-MS are lower and 
additional information regarding identity of peaks is possible.  
An internal standard was used for each of the analyses. The substances were added prior to 
sample analysis and in some instances prior to sample manipulation. There are large 
variations in the responses of the internal standards. These variations are accompanied by 
similar fluctuations in analyte response. The purpose of the internal standard is illustrated 
here as losses due to poor injector reproducibility or sample manipulation can be accounted 
for. The calculation of the ratio between internal standard response and analyte response 
instead of using the individual responses is more accurate.  
 
 
 
 
 
 
